Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: A meta-analysis and meta-regression
Many studies have explored the association between soluble interleukin-2 receptor (sIL-2R), cytokines and major depressive disorder (MDD). However, the results of these studies were not consistent. The aim of our study is to compare the levels of sIL-2R and cytokines in the blood between MDD patient...
Saved in:
| Published in | Journal of affective disorders Vol. 139; no. 3; pp. 230 - 239 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
Oxford
Elsevier B.V
01.08.2012
Elsevier |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0165-0327 1573-2517 1573-2517 |
| DOI | 10.1016/j.jad.2011.08.003 |
Cover
| Abstract | Many studies have explored the association between soluble interleukin-2 receptor (sIL-2R), cytokines and major depressive disorder (MDD). However, the results of these studies were not consistent. The aim of our study is to compare the levels of sIL-2R and cytokines in the blood between MDD patients and controls by a meta-analysis and to identify moderators accounting for potential heterogeneity in the levels of sIL-2R and cytokines in MDD patients versus controls by meta-regression analyses.
A comprehensive literature search was performed to identify studies comparing the levels of sIL-2R and cytokines between MDD patients and controls. We pooled the effect sizes for standardized mean differences (SMD) of the levels of sIL-2R and cytokines. We also performed meta-regression and sensitivity analyses to investigate the roles of age, gender, sample type, ethnic origin and selected studies' quality in explaining potential heterogeneity and differences in results respectively.
Twenty-nine studies were selected for this analysis. The levels of sIL-2R, TNF-α and IL-6 in MDD patients were significantly higher than those of healthy controls (SMD=0.555, p<0.001, SMD=0.567, p=0.010; SMD=0.680, p<0.001). Mean age of all subjects was a significant moderator to explain the high heterogeneity of IL-6. Sensitivity analysis found that European but not non-European subjects have higher levels difference of sIL-2R, TNF-α and IL-1β between MDD patients and controls.
The severity of MDD was not considered.
The blood levels of sIL-2R, TNF-α and IL-6 were significantly higher in MDD patients than controls. Age, samples source and ethnic origins may play a potential role in heterogeneity. |
|---|---|
| AbstractList | Many studies have explored the association between soluble interleukin-2 receptor (sIL-2R), cytokines and major depressive disorder (MDD). However, the results of these studies were not consistent. The aim of our study is to compare the levels of sIL-2R and cytokines in the blood between MDD patients and controls by a meta-analysis and to identify moderators accounting for potential heterogeneity in the levels of sIL-2R and cytokines in MDD patients versus controls by meta-regression analyses.
A comprehensive literature search was performed to identify studies comparing the levels of sIL-2R and cytokines between MDD patients and controls. We pooled the effect sizes for standardized mean differences (SMD) of the levels of sIL-2R and cytokines. We also performed meta-regression and sensitivity analyses to investigate the roles of age, gender, sample type, ethnic origin and selected studies' quality in explaining potential heterogeneity and differences in results respectively.
Twenty-nine studies were selected for this analysis. The levels of sIL-2R, TNF-α and IL-6 in MDD patients were significantly higher than those of healthy controls (SMD=0.555, p<0.001, SMD=0.567, p=0.010; SMD=0.680, p<0.001). Mean age of all subjects was a significant moderator to explain the high heterogeneity of IL-6. Sensitivity analysis found that European but not non-European subjects have higher levels difference of sIL-2R, TNF-α and IL-1β between MDD patients and controls.
The severity of MDD was not considered.
The blood levels of sIL-2R, TNF-α and IL-6 were significantly higher in MDD patients than controls. Age, samples source and ethnic origins may play a potential role in heterogeneity. Many studies have explored the association between soluble interleukin-2 receptor (sIL-2R), cytokines and major depressive disorder (MDD). However, the results of these studies were not consistent. The aim of our study is to compare the levels of sIL-2R and cytokines in the blood between MDD patients and controls by a meta-analysis and to identify moderators accounting for potential heterogeneity in the levels of sIL-2R and cytokines in MDD patients versus controls by meta-regression analyses.BACKGROUNDMany studies have explored the association between soluble interleukin-2 receptor (sIL-2R), cytokines and major depressive disorder (MDD). However, the results of these studies were not consistent. The aim of our study is to compare the levels of sIL-2R and cytokines in the blood between MDD patients and controls by a meta-analysis and to identify moderators accounting for potential heterogeneity in the levels of sIL-2R and cytokines in MDD patients versus controls by meta-regression analyses.A comprehensive literature search was performed to identify studies comparing the levels of sIL-2R and cytokines between MDD patients and controls. We pooled the effect sizes for standardized mean differences (SMD) of the levels of sIL-2R and cytokines. We also performed meta-regression and sensitivity analyses to investigate the roles of age, gender, sample type, ethnic origin and selected studies' quality in explaining potential heterogeneity and differences in results respectively.METHODSA comprehensive literature search was performed to identify studies comparing the levels of sIL-2R and cytokines between MDD patients and controls. We pooled the effect sizes for standardized mean differences (SMD) of the levels of sIL-2R and cytokines. We also performed meta-regression and sensitivity analyses to investigate the roles of age, gender, sample type, ethnic origin and selected studies' quality in explaining potential heterogeneity and differences in results respectively.Twenty-nine studies were selected for this analysis. The levels of sIL-2R, TNF-α and IL-6 in MDD patients were significantly higher than those of healthy controls (SMD=0.555, p<0.001, SMD=0.567, p=0.010; SMD=0.680, p<0.001). Mean age of all subjects was a significant moderator to explain the high heterogeneity of IL-6. Sensitivity analysis found that European but not non-European subjects have higher levels difference of sIL-2R, TNF-α and IL-1β between MDD patients and controls.RESULTSTwenty-nine studies were selected for this analysis. The levels of sIL-2R, TNF-α and IL-6 in MDD patients were significantly higher than those of healthy controls (SMD=0.555, p<0.001, SMD=0.567, p=0.010; SMD=0.680, p<0.001). Mean age of all subjects was a significant moderator to explain the high heterogeneity of IL-6. Sensitivity analysis found that European but not non-European subjects have higher levels difference of sIL-2R, TNF-α and IL-1β between MDD patients and controls.The severity of MDD was not considered.LIMITATIONThe severity of MDD was not considered.The blood levels of sIL-2R, TNF-α and IL-6 were significantly higher in MDD patients than controls. Age, samples source and ethnic origins may play a potential role in heterogeneity.CONCLUSIONThe blood levels of sIL-2R, TNF-α and IL-6 were significantly higher in MDD patients than controls. Age, samples source and ethnic origins may play a potential role in heterogeneity. Background: Many studies have explored the association between soluble interleukin-2 receptor (sIL-2R), cytokines and major depressive disorder (MDD). However, the results of these studies were not consistent. The aim of our study is to compare the levels of sIL-2R and cytokines in the blood between MDD patients and controls by a meta-analysis and to identify moderators accounting for potential heterogeneity in the levels of sIL-2R and cytokines in MDD patients versus controls by meta-regression analyses. Methods: A comprehensive literature search was performed to identify studies comparing the levels of sIL-2R and cytokines between MDD patients and controls. We pooled the effect sizes for standardized mean differences (SMD) of the levels of sIL-2R and cytokines. We also performed meta-regression and sensitivity analyses to investigate the roles of age, gender, sample type, ethnic origin and selected studies' quality in explaining potential heterogeneity and differences in results respectively. Results: Twenty-nine studies were selected for this analysis. The levels of sIL-2R, TNF- and IL-6 in MDD patients were significantly higher than those of healthy controls (SMD=0.555, p<0.001, SMD=0.567, p=0.010; SMD=0.680, p<0.001). Mean age of all subjects was a significant moderator to explain the high heterogeneity of IL-6. Sensitivity analysis found that European but not non-European subjects have higher levels difference of sIL-2R, TNF- and IL-1 between MDD patients and controls. [Copyright Elsevier B.V.] AbstractBackgroundMany studies have explored the association between soluble interleukin-2 receptor (sIL-2R), cytokines and major depressive disorder (MDD). However, the results of these studies were not consistent. The aim of our study is to compare the levels of sIL-2R and cytokines in the blood between MDD patients and controls by a meta-analysis and to identify moderators accounting for potential heterogeneity in the levels of sIL-2R and cytokines in MDD patients versus controls by meta-regression analyses. MethodsA comprehensive literature search was performed to identify studies comparing the levels of sIL-2R and cytokines between MDD patients and controls. We pooled the effect sizes for standardized mean differences (SMD) of the levels of sIL-2R and cytokines. We also performed meta-regression and sensitivity analyses to investigate the roles of age, gender, sample type, ethnic origin and selected studies' quality in explaining potential heterogeneity and differences in results respectively. ResultsTwenty-nine studies were selected for this analysis. The levels of sIL-2R, TNF-α and IL-6 in MDD patients were significantly higher than those of healthy controls (SMD = 0.555, p < 0.001, SMD = 0.567, p = 0.010; SMD = 0.680, p < 0.001). Mean age of all subjects was a significant moderator to explain the high heterogeneity of IL-6. Sensitivity analysis found that European but not non-European subjects have higher levels difference of sIL-2R, TNF-α and IL-1β between MDD patients and controls. LimitationThe severity of MDD was not considered. ConclusionThe blood levels of sIL-2R, TNF-α and IL-6 were significantly higher in MDD patients than controls. Age, samples source and ethnic origins may play a potential role in heterogeneity. |
| Author | Mak, Anselm Liu, Yang Ho, Roger Chun-Man |
| Author_xml | – sequence: 1 givenname: Yang surname: Liu fullname: Liu, Yang organization: Department of Psychological Medicine, University Medicine Cluster, National University Health System, Yong Loo Lin School of Medicine, National University of Singapore, Singapore – sequence: 2 givenname: Roger Chun-Man surname: Ho fullname: Ho, Roger Chun-Man email: roger_ho@nuhs.edu.sg organization: Department of Psychological Medicine, University Medicine Cluster, National University Health System, Yong Loo Lin School of Medicine, National University of Singapore, Singapore – sequence: 3 givenname: Anselm surname: Mak fullname: Mak, Anselm organization: Department of Medicine, University Medicine Cluster, National University Health System, Yong Loo Lin School of Medicine, National University of Singapore, Singapore |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26042790$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21872339$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNktFqFDEYhQep2Hb1AbyR3AhbcNYkM5nMKAilWF1YFLReh0zyr810JjMmmZV9LJ_Be5_JTHdLoWDrVSB85_zJ-c9xcmB7C0nynOAFwaR43SwaqRcUE7LA5QLj7FFyRBjPUsoIP0iOIsNSnFF-mBx732CMi4rjJ8khJSWnWVYdJb-XNoBrYbwyFs2Xq5O0eIXC2PWjQxaU673xaC1V6B2S7XAp0fzi03n659cJklYj37dj3QIyty4pRQ4UDFHh0dwvVyn9EmEHCFrYyAA60miQwYANHv004RJ1son-GgYH3psNIG187zS4N-gUdRBkKq1st9NbpqnXNw6-X9O9fZo8XsvWw7P9OUu-nb-_OPuYrj5_WJ6drlLFWB7SfI2rGIYGyjWri4rkUhdMZxVUkhVKlwQ4pZRBXuWyquqay5IR0DXPYtqyymbJfOc7uP7HCD6IzngFbSst9KMXhBcx8Bzz8mEUZyUhhJXZf6AU47wsi-kBL_boWHegxeBMJ91W3KwzAi_3gPRKtmsnrTL-litwTnkMYZbwHTct2DtYC2VC3Ehvg5OmjTPFVDDRiFgwMRVM4FLEgkUluaO8Mb9P83angbicjQEnvIrLV6BNbEoQujf3qt_dUavWWBO_dwVb8E1sauxGzEl4KrD4OpV-6jwhMbYCs2hQ_dvggeF_AduuD9g |
| CODEN | JADID7 |
| CitedBy_id | crossref_primary_10_1038_s41398_024_02902_2 crossref_primary_10_1016_j_psyneuen_2024_107094 crossref_primary_10_1007_s12035_018_1016_x crossref_primary_10_18229_kocatepetip_1242016 crossref_primary_10_1016_j_jpsychires_2021_09_054 crossref_primary_10_1016_j_psychres_2018_11_069 crossref_primary_10_1007_s13311_020_00893_8 crossref_primary_10_1016_j_psychres_2018_11_064 crossref_primary_10_1016_j_psyneuen_2015_10_008 crossref_primary_10_1159_000466698 crossref_primary_10_1016_j_neuropharm_2012_10_002 crossref_primary_10_1007_s00213_012_2923_6 crossref_primary_10_1016_j_bbi_2023_10_011 crossref_primary_10_1016_j_mehy_2020_110061 crossref_primary_10_3390_brainsci11040411 crossref_primary_10_3389_fpsyt_2020_568929 crossref_primary_10_1016_j_pnpbp_2016_09_003 crossref_primary_10_1590_0101_60830000000184 crossref_primary_10_1016_j_bbi_2020_04_028 crossref_primary_10_1016_j_jad_2014_06_050 crossref_primary_10_3390_ijerph14121566 crossref_primary_10_1155_2017_1469209 crossref_primary_10_1016_j_yfrne_2019_100772 crossref_primary_10_1016_j_jad_2018_12_100 crossref_primary_10_1097_MD_0000000000001520 crossref_primary_10_1016_j_psychres_2018_03_073 crossref_primary_10_1016_j_neuroscience_2018_12_008 crossref_primary_10_1016_j_brainres_2014_06_008 crossref_primary_10_5213_inj_1938226_113 crossref_primary_10_1159_000444531 crossref_primary_10_3389_fnins_2014_00416 crossref_primary_10_1016_j_pbb_2022_173448 crossref_primary_10_1016_j_bbr_2022_113813 crossref_primary_10_1016_j_pnpbp_2017_04_023 crossref_primary_10_1016_j_bbr_2016_09_004 crossref_primary_10_1111_hdi_12200 crossref_primary_10_1016_j_schres_2018_06_037 crossref_primary_10_1186_s12888_023_05248_z crossref_primary_10_2174_1570159X16666180302120322 crossref_primary_10_3390_ijms22041532 crossref_primary_10_1007_s40120_022_00368_2 crossref_primary_10_1016_j_neubiorev_2018_03_023 crossref_primary_10_3389_fpsyt_2017_00108 crossref_primary_10_3390_brainsci11121612 crossref_primary_10_1007_s00394_016_1373_z crossref_primary_10_1007_s40211_023_00487_8 crossref_primary_10_1038_mp_2016_3 crossref_primary_10_1080_19371918_2024_2340082 crossref_primary_10_1016_j_drudis_2023_103804 crossref_primary_10_1111_bdi_12259 crossref_primary_10_2147_PRBM_S482409 crossref_primary_10_1017_S0033291722000113 crossref_primary_10_1016_j_jep_2014_11_031 crossref_primary_10_1016_j_phrs_2023_106893 crossref_primary_10_1186_1745_6215_13_106 crossref_primary_10_1007_s12035_015_9443_4 crossref_primary_10_3390_nu13030767 crossref_primary_10_1093_ijnp_pyw001 crossref_primary_10_1016_j_bbih_2020_100090 crossref_primary_10_1080_2314808X_2024_2343974 crossref_primary_10_1016_j_mehy_2019_109404 crossref_primary_10_1038_s41380_018_0017_5 crossref_primary_10_1517_14728222_2014_888417 crossref_primary_10_1007_s11136_020_02445_1 crossref_primary_10_1016_j_biopsych_2018_12_020 crossref_primary_10_1016_j_bbi_2024_12_006 crossref_primary_10_1016_j_jad_2019_07_002 crossref_primary_10_1080_03007995_2024_2360647 crossref_primary_10_1007_s00213_022_06107_7 crossref_primary_10_1007_s12474_013_0030_z crossref_primary_10_1007_s12160_012_9443_9 crossref_primary_10_1371_journal_pone_0111665 crossref_primary_10_3389_fpsyt_2023_1216583 crossref_primary_10_1038_s41380_024_02577_7 crossref_primary_10_1016_j_bbi_2012_10_007 crossref_primary_10_1038_nrn3839 crossref_primary_10_1016_j_phrs_2018_06_015 crossref_primary_10_1021_acs_analchem_3c05981 crossref_primary_10_1002_brb3_3467 crossref_primary_10_1016_j_euroneuro_2020_11_016 crossref_primary_10_1007_s11920_015_0601_1 crossref_primary_10_3389_fmed_2022_765461 crossref_primary_10_1002_mnfr_202300461 crossref_primary_10_1002_cam4_5043 crossref_primary_10_1016_j_neuropharm_2022_109345 crossref_primary_10_1016_j_ultrasmedbio_2018_09_005 crossref_primary_10_3390_brainsci12070939 crossref_primary_10_1186_1741_7015_10_66 crossref_primary_10_1016_j_jpsychires_2021_09_057 crossref_primary_10_1016_j_socscimed_2024_117540 crossref_primary_10_30565_medalanya_880254 crossref_primary_10_1016_j_bbih_2021_100259 crossref_primary_10_1038_s41398_019_0528_0 crossref_primary_10_3390_ijms17122022 crossref_primary_10_1016_j_jpsychires_2022_12_046 crossref_primary_10_1016_j_bbih_2022_100554 crossref_primary_10_3389_fncel_2016_00086 crossref_primary_10_7759_cureus_52890 crossref_primary_10_1016_j_bbih_2021_100313 crossref_primary_10_1016_j_ecoenv_2023_114770 crossref_primary_10_1017_S1092852922001043 crossref_primary_10_1080_14737175_2018_1407242 crossref_primary_10_1016_j_drugalcdep_2021_108610 crossref_primary_10_1016_j_jad_2024_11_071 crossref_primary_10_1016_j_npbr_2018_10_001 crossref_primary_10_1002_brb3_1359 crossref_primary_10_1016_j_bbadis_2020_165752 crossref_primary_10_1111_cns_12303 crossref_primary_10_1089_jwh_2016_6254 crossref_primary_10_1007_s12035_016_9741_5 crossref_primary_10_1016_j_medici_2016_05_003 crossref_primary_10_4306_pi_2016_13_1_18 crossref_primary_10_1111_bjd_18008 crossref_primary_10_1016_j_neuropharm_2022_109351 crossref_primary_10_1007_s44337_024_00114_7 crossref_primary_10_1016_j_bbih_2021_100308 crossref_primary_10_1016_j_heliyon_2024_e33157 crossref_primary_10_1302_0301_620X_98B7_37152 crossref_primary_10_3390_cimb45090484 crossref_primary_10_9758_cpn_2021_19_1_12 crossref_primary_10_1155_2015_716920 crossref_primary_10_1155_2021_5518138 crossref_primary_10_1016_j_bbi_2017_05_005 crossref_primary_10_1007_s10495_019_01530_2 crossref_primary_10_1080_07420528_2019_1661424 crossref_primary_10_1038_s41467_024_47273_w crossref_primary_10_1111_pcn_12826 crossref_primary_10_1007_s40263_022_00931_3 crossref_primary_10_3390_ijms22116138 crossref_primary_10_1016_j_taap_2019_114688 crossref_primary_10_1155_2020_3050487 crossref_primary_10_1016_j_biopha_2023_114847 crossref_primary_10_3389_fpsyt_2022_925007 crossref_primary_10_1002_hup_2434 crossref_primary_10_1016_j_psychres_2016_05_021 crossref_primary_10_1016_j_cbi_2020_109134 crossref_primary_10_3389_fpsyt_2015_00138 crossref_primary_10_1080_03007995_2021_1900088 crossref_primary_10_3389_fpsyt_2023_1097196 crossref_primary_10_3390_ijms232012453 crossref_primary_10_1038_s41584_023_01037_w crossref_primary_10_1007_s40501_024_00321_0 crossref_primary_10_1080_14737175_2017_1341310 crossref_primary_10_1016_j_bbi_2021_12_003 crossref_primary_10_1016_j_neubiorev_2016_07_003 crossref_primary_10_1007_s12640_017_9835_5 crossref_primary_10_1186_s12888_024_06163_7 crossref_primary_10_3390_microorganisms11092286 crossref_primary_10_1111_acps_12182 crossref_primary_10_1111_psyg_13235 crossref_primary_10_1002_gps_4512 crossref_primary_10_1016_j_intimp_2023_110043 crossref_primary_10_3390_biomedicines11061600 crossref_primary_10_1007_s11920_019_1075_3 crossref_primary_10_1017_S1092852919001469 crossref_primary_10_1155_2016_8926840 crossref_primary_10_1038_srep39940 crossref_primary_10_1002_0471142301_ns0946s65 crossref_primary_10_1007_s11011_012_9371_1 crossref_primary_10_1159_000441457 crossref_primary_10_1177_1948550613494226 crossref_primary_10_1016_j_bbi_2019_08_002 crossref_primary_10_1080_15622975_2022_2045354 crossref_primary_10_1038_s41398_021_01259_0 crossref_primary_10_1080_15622975_2016_1208843 crossref_primary_10_1016_j_jpsychires_2023_03_019 crossref_primary_10_1016_j_pharmthera_2022_108279 crossref_primary_10_1515_tnsci_2020_0167 crossref_primary_10_1016_j_psyneuen_2020_104609 crossref_primary_10_3389_fpsyt_2022_822466 crossref_primary_10_1080_19768354_2015_1121918 crossref_primary_10_1007_s00213_013_3322_3 crossref_primary_10_1016_j_cct_2015_07_002 crossref_primary_10_1016_j_nsa_2023_101136 crossref_primary_10_1186_s12993_016_0116_x crossref_primary_10_1002_gps_4522 crossref_primary_10_1016_j_jad_2020_09_108 crossref_primary_10_1016_j_ijpharm_2021_120670 crossref_primary_10_1111_prd_12036 crossref_primary_10_1016_j_jpsychires_2022_12_009 crossref_primary_10_1016_j_bbi_2020_11_024 crossref_primary_10_1002_mds_29056 crossref_primary_10_1186_s12974_021_02100_7 crossref_primary_10_1038_s41398_022_02297_y crossref_primary_10_3389_fcvm_2023_1072042 crossref_primary_10_3390_cells14030164 crossref_primary_10_3390_biomedicines9070734 crossref_primary_10_1186_1742_2094_10_43 crossref_primary_10_1016_j_jad_2022_02_069 crossref_primary_10_1016_j_yfrne_2019_100800 crossref_primary_10_1186_s12991_024_00522_0 crossref_primary_10_1016_j_physbeh_2014_11_058 crossref_primary_10_1007_s10753_016_0332_4 crossref_primary_10_1016_j_bbr_2016_05_063 crossref_primary_10_1155_2021_5537523 crossref_primary_10_1089_cap_2019_0015 crossref_primary_10_1016_j_pnpbp_2020_110151 crossref_primary_10_1016_j_tips_2014_04_003 crossref_primary_10_3390_biomedicines9080897 crossref_primary_10_1016_j_ajcnut_2023_01_018 crossref_primary_10_1016_j_neubiorev_2014_01_008 crossref_primary_10_1177_0300060520918419 crossref_primary_10_3389_fnins_2022_1006031 crossref_primary_10_1016_j_psyneuen_2022_105867 crossref_primary_10_1192_bja_2017_27 crossref_primary_10_1002_hup_2588 crossref_primary_10_3390_ph17070841 crossref_primary_10_1155_da_4907389 crossref_primary_10_1590_0101_60830000000222 crossref_primary_10_3389_fpsyt_2014_00136 crossref_primary_10_1016_j_jpsychires_2022_10_071 crossref_primary_10_1016_j_jad_2024_06_093 crossref_primary_10_1016_j_jpsychires_2014_07_012 crossref_primary_10_1038_s41398_022_01883_4 crossref_primary_10_1136_thoraxjnl_2021_217612 crossref_primary_10_3923_asb_2024_112_122 crossref_primary_10_1038_tp_2014_56 crossref_primary_10_1016_j_psychres_2024_116141 crossref_primary_10_1111_ejn_14712 crossref_primary_10_2147_JIR_S387588 crossref_primary_10_4000_pistes_3376 crossref_primary_10_1016_S2215_0366_17_30333_4 crossref_primary_10_1038_s41398_017_0016_3 crossref_primary_10_1186_s12888_024_05730_2 crossref_primary_10_1186_s12889_024_19563_x crossref_primary_10_2174_1573399818666220411122345 crossref_primary_10_1016_j_jff_2020_104106 crossref_primary_10_1007_s11920_015_0618_5 crossref_primary_10_1016_j_bbi_2019_06_003 crossref_primary_10_1016_j_bbi_2015_06_001 crossref_primary_10_1016_j_jpsychires_2024_08_025 crossref_primary_10_1080_23744235_2022_2043560 crossref_primary_10_1016_j_bbi_2013_10_007 crossref_primary_10_1016_j_psyneuen_2012_10_003 crossref_primary_10_14412_2074_2711_2022_5_22_27 crossref_primary_10_3389_fpsyt_2022_949477 crossref_primary_10_2174_1570159X17666191001142934 crossref_primary_10_1016_j_intimp_2017_05_017 crossref_primary_10_1016_j_jad_2019_05_028 crossref_primary_10_2147_NDT_S357797 crossref_primary_10_1097_MD_0000000000034172 crossref_primary_10_1186_s42358_021_00223_2 crossref_primary_10_1016_j_ejpsy_2022_04_002 crossref_primary_10_1039_D0RA07551E crossref_primary_10_1016_j_brainresbull_2021_03_002 crossref_primary_10_3390_ijerph15102073 crossref_primary_10_1038_npp_2012_121 crossref_primary_10_1007_s00228_021_03240_8 crossref_primary_10_1016_j_plefa_2017_05_001 crossref_primary_10_1016_j_envres_2025_121148 crossref_primary_10_2217_bmm_14_29 crossref_primary_10_1016_j_bbi_2017_10_025 crossref_primary_10_1080_13548506_2019_1710545 crossref_primary_10_1111_jsr_13035 crossref_primary_10_1155_2015_684025 crossref_primary_10_62347_WVVG5364 crossref_primary_10_1016_j_brainres_2018_05_032 crossref_primary_10_1016_j_jad_2022_11_091 crossref_primary_10_1016_j_lfs_2021_119407 crossref_primary_10_1016_j_jad_2013_10_019 crossref_primary_10_6061_clinics_2018_e177 crossref_primary_10_1016_j_bbr_2017_07_041 crossref_primary_10_1177_10815589241251702 crossref_primary_10_1002_pon_4316 crossref_primary_10_1016_j_jpsychires_2023_10_009 crossref_primary_10_1007_s00167_015_3628_2 crossref_primary_10_1016_j_bbrc_2018_05_085 crossref_primary_10_1155_2024_4062632 crossref_primary_10_1590_1806_9282_65_3_361 crossref_primary_10_1038_s41598_018_31530_2 crossref_primary_10_15690_pf_v21i3_2757 crossref_primary_10_1016_j_jad_2016_03_036 crossref_primary_10_1590_0101_60830000000212 crossref_primary_10_1002_cam4_3380 crossref_primary_10_1177_0004867413488220 crossref_primary_10_1007_s40521_017_0110_z crossref_primary_10_1016_j_pnpbp_2017_09_015 crossref_primary_10_1111_cen3_12389 crossref_primary_10_1016_j_bbih_2020_100118 crossref_primary_10_1111_jcpt_12287 crossref_primary_10_1016_j_jad_2020_09_025 crossref_primary_10_1016_j_jpsychores_2018_09_008 crossref_primary_10_3389_fpsyg_2020_01271 crossref_primary_10_1016_j_bbi_2023_04_011 crossref_primary_10_1093_rheumatology_kex528 crossref_primary_10_1016_j_jpain_2015_06_004 crossref_primary_10_1038_aps_2016_145 crossref_primary_10_1016_j_expneurol_2019_04_001 crossref_primary_10_1016_j_bbi_2018_05_012 crossref_primary_10_1007_s11356_021_14884_5 crossref_primary_10_1016_j_jad_2023_11_070 crossref_primary_10_1007_s00127_020_01966_x crossref_primary_10_1016_j_brainresbull_2022_07_001 crossref_primary_10_1016_j_psyneuen_2014_09_031 crossref_primary_10_1016_j_psychres_2020_113065 crossref_primary_10_3390_cells13231988 crossref_primary_10_1007_s11356_021_18317_1 crossref_primary_10_1111_1750_3841_17368 crossref_primary_10_3389_fpsyt_2020_00641 crossref_primary_10_1016_j_fct_2019_110803 crossref_primary_10_1111_jop_12666 crossref_primary_10_2147_JIR_S439912 crossref_primary_10_3390_toxins13070450 crossref_primary_10_1007_s00702_018_1844_x crossref_primary_10_15829_1728_8800_2024_3767 crossref_primary_10_1152_ajpheart_00244_2020 crossref_primary_10_1186_2045_5380_4_10 crossref_primary_10_1007_s11011_019_00466_5 crossref_primary_10_3390_pathogens12030361 crossref_primary_10_1038_s41380_021_01065_6 crossref_primary_10_1155_2016_2986090 crossref_primary_10_1016_j_jep_2024_119224 crossref_primary_10_3389_fpsyt_2021_642976 crossref_primary_10_1159_000356549 crossref_primary_10_1007_s40263_016_0328_5 crossref_primary_10_1016_j_socscimed_2021_114191 crossref_primary_10_1016_j_jpsychires_2012_12_001 crossref_primary_10_1177_0269881112458732 crossref_primary_10_1016_j_jpet_2025_103563 crossref_primary_10_3389_fpsyt_2020_572533 crossref_primary_10_1002_pchj_87 crossref_primary_10_1016_j_jneuroim_2015_03_012 crossref_primary_10_1155_2018_6450962 crossref_primary_10_1016_j_bpsc_2023_04_011 crossref_primary_10_1016_j_jocn_2019_10_002 crossref_primary_10_1016_j_neulet_2014_03_056 crossref_primary_10_3389_fncel_2015_00040 crossref_primary_10_1016_j_fsi_2017_02_007 crossref_primary_10_1097_MIB_0000000000001107 crossref_primary_10_1186_s12868_015_0169_z crossref_primary_10_1089_eco_2020_0010 crossref_primary_10_1111_bcpt_13455 crossref_primary_10_1016_j_bbi_2015_08_005 crossref_primary_10_1016_j_cyto_2020_155030 crossref_primary_10_1016_j_jad_2018_10_106 crossref_primary_10_1007_s10067_023_06806_2 crossref_primary_10_1016_j_mehy_2015_01_033 crossref_primary_10_1177_02537176241279110 crossref_primary_10_3390_ijerph15050865 crossref_primary_10_1016_j_psychres_2022_114725 crossref_primary_10_1038_s41398_023_02383_9 crossref_primary_10_3389_fneur_2021_719088 crossref_primary_10_1016_j_pnpbp_2018_03_012 crossref_primary_10_1016_j_jpsychires_2017_05_004 crossref_primary_10_1080_09291016_2019_1587837 crossref_primary_10_4306_pi_2016_13_6_644 crossref_primary_10_1016_j_alcohol_2015_01_012 crossref_primary_10_1016_j_jad_2023_05_059 crossref_primary_10_1007_s12264_016_0094_x crossref_primary_10_1177_0004867417701996 crossref_primary_10_1016_j_bbi_2015_08_009 crossref_primary_10_1055_s_0043_1776981 crossref_primary_10_1155_2013_873278 crossref_primary_10_1016_j_bbr_2020_112501 crossref_primary_10_1002_adbi_202200214 crossref_primary_10_1016_j_biopsych_2014_09_023 crossref_primary_10_1002_jmv_23711 crossref_primary_10_1038_s41398_021_01755_3 crossref_primary_10_1016_j_ijbiomac_2018_09_171 crossref_primary_10_1186_s12888_024_06463_y crossref_primary_10_1016_j_neuron_2020_06_002 crossref_primary_10_3389_fncel_2014_00391 crossref_primary_10_1186_s12916_015_0310_y crossref_primary_10_7759_cureus_62991 crossref_primary_10_1038_s41398_021_01668_1 crossref_primary_10_4103_ijoy_ijoy_60_21 crossref_primary_10_1016_j_jad_2020_07_041 crossref_primary_10_1111_ejn_14547 crossref_primary_10_1016_j_psyneuen_2021_105625 crossref_primary_10_1038_mp_2012_33 crossref_primary_10_1016_j_alcohol_2019_02_001 crossref_primary_10_1186_s12888_017_1515_8 crossref_primary_10_1016_j_brainres_2019_146398 crossref_primary_10_1111_ejn_15992 crossref_primary_10_1016_j_biopsych_2013_07_041 crossref_primary_10_1002_advs_202412556 crossref_primary_10_1111_obr_12535 crossref_primary_10_1177_0269881117746902 crossref_primary_10_1080_14789450_2018_1544894 crossref_primary_10_1016_j_jpsychires_2017_03_018 crossref_primary_10_1007_s10989_018_9686_9 crossref_primary_10_1016_j_jpsychires_2016_01_008 crossref_primary_10_1017_S0033291718000090 crossref_primary_10_1586_14737175_2015_1008457 crossref_primary_10_1016_j_jad_2014_10_030 crossref_primary_10_1155_2017_5071786 crossref_primary_10_1289_EHP4595 crossref_primary_10_1007_s11055_019_00848_3 crossref_primary_10_1016_j_jad_2025_02_053 crossref_primary_10_1016_j_mehy_2016_06_001 crossref_primary_10_1007_s11481_016_9712_7 crossref_primary_10_3390_brainsci13111561 crossref_primary_10_3390_medicina57040315 crossref_primary_10_1111_acps_12211 crossref_primary_10_3389_fimmu_2020_01170 crossref_primary_10_1016_j_eurpsy_2017_02_479 crossref_primary_10_4137_CMPsy_S20765 crossref_primary_10_1016_j_bbr_2022_114237 crossref_primary_10_1038_tp_2015_100 crossref_primary_10_1016_j_nsa_2024_104051 crossref_primary_10_3390_jcm9123793 crossref_primary_10_1177_00912174231190455 crossref_primary_10_1136_jnnp_2019_320912 crossref_primary_10_1097_WNR_0000000000000637 crossref_primary_10_1016_j_nsa_2023_103923 crossref_primary_10_3389_fnmol_2018_00127 crossref_primary_10_1002_fsn3_4073 crossref_primary_10_1007_s12035_018_1306_3 crossref_primary_10_1007_s12144_021_01396_1 crossref_primary_10_1177_0269881114529377 crossref_primary_10_3389_fpsyt_2024_1419574 crossref_primary_10_5127_pr_034413 crossref_primary_10_1016_j_ijbiomac_2019_04_031 crossref_primary_10_1186_1742_2094_10_142 crossref_primary_10_1371_journal_pone_0151862 crossref_primary_10_3390_ijerph15040578 crossref_primary_10_1016_j_neulet_2013_10_012 crossref_primary_10_1111_aji_13619 crossref_primary_10_1016_j_brainresbull_2018_10_010 crossref_primary_10_3389_fncel_2021_608656 crossref_primary_10_1016_j_jep_2015_01_022 crossref_primary_10_3389_fneur_2018_00167 crossref_primary_10_1017_S0033291721003767 crossref_primary_10_1007_s43440_021_00301_8 crossref_primary_10_1016_j_bbr_2024_115098 crossref_primary_10_1016_j_genhosppsych_2019_02_003 crossref_primary_10_1016_j_bbi_2012_06_007 crossref_primary_10_1093_rheumatology_kez559 crossref_primary_10_1016_j_jad_2018_09_048 crossref_primary_10_1016_j_cyto_2020_155066 crossref_primary_10_1016_j_bbi_2012_06_001 crossref_primary_10_1152_ajpheart_00859_2014 crossref_primary_10_1016_j_jad_2022_04_048 crossref_primary_10_1093_aje_kwz254 crossref_primary_10_1038_s41398_024_02950_8 crossref_primary_10_1016_j_jad_2019_04_048 crossref_primary_10_1016_j_jad_2013_06_004 crossref_primary_10_1192_bjo_2018_84 crossref_primary_10_1039_C9FO00219G crossref_primary_10_3389_fimmu_2023_1007624 crossref_primary_10_1016_j_biopsych_2017_06_020 crossref_primary_10_1016_j_psychres_2016_02_022 crossref_primary_10_1016_j_intimp_2020_106615 crossref_primary_10_1017_neu_2019_17 crossref_primary_10_1038_s41598_023_38410_4 crossref_primary_10_1093_cercor_bhae149 crossref_primary_10_1016_j_bbih_2024_100759 crossref_primary_10_1186_1741_7015_11_129 crossref_primary_10_3390_ijms17050733 crossref_primary_10_1016_j_bbi_2021_01_016 crossref_primary_10_18699_VJ19_515 crossref_primary_10_1016_j_psyneuen_2014_03_019 crossref_primary_10_1177_2045125318791944 crossref_primary_10_1016_j_bbi_2012_05_010 crossref_primary_10_3109_01612840_2013_875086 crossref_primary_10_1038_s41398_018_0256_x crossref_primary_10_1016_j_bbi_2020_01_011 crossref_primary_10_1186_s12876_023_02993_z crossref_primary_10_1016_j_physbeh_2020_113297 crossref_primary_10_1016_j_bbi_2019_03_004 crossref_primary_10_1038_s41398_024_03216_z crossref_primary_10_1177_2059902118792434 crossref_primary_10_1038_npp_2016_116 crossref_primary_10_1021_acs_jmedchem_4c00831 crossref_primary_10_3892_br_2016_807 crossref_primary_10_1177_20587392211047646 crossref_primary_10_3390_jcm10184142 crossref_primary_10_1002_brb3_933 crossref_primary_10_1016_j_ijbiomac_2018_10_080 crossref_primary_10_1016_j_carbpol_2015_07_070 crossref_primary_10_1038_s41598_017_06179_y crossref_primary_10_1080_14737175_2019_1580145 crossref_primary_10_1097_PSY_0000000000000339 crossref_primary_10_1111_pcn_12386 crossref_primary_10_1016_j_ecoenv_2024_117658 crossref_primary_10_1192_apt_bp_114_012872 crossref_primary_10_3390_ijerph16122081 crossref_primary_10_3390_ph14070659 crossref_primary_10_3389_fmolb_2022_859760 crossref_primary_10_3389_fpsyt_2021_797577 crossref_primary_10_1007_s00406_023_01617_7 crossref_primary_10_3389_fnut_2021_656290 crossref_primary_10_3390_molecules26082368 crossref_primary_10_1016_j_pnpbp_2015_11_012 crossref_primary_10_1186_s13063_018_2829_7 crossref_primary_10_1186_s12868_020_0551_3 crossref_primary_10_3389_fphar_2017_00779 crossref_primary_10_1192_apt_bp_116_016311 crossref_primary_10_1176_appi_focus_16206 crossref_primary_10_3390_ijerph19116846 crossref_primary_10_1007_s11010_019_03668_8 crossref_primary_10_1158_1055_9965_EPI_17_0707 crossref_primary_10_1007_s12035_024_04614_6 crossref_primary_10_1016_j_bbi_2024_06_003 crossref_primary_10_1016_j_biopsych_2013_05_008 crossref_primary_10_3389_fimmu_2016_00655 crossref_primary_10_1016_j_colsurfb_2020_111209 crossref_primary_10_1002_da_23045 crossref_primary_10_1007_s40264_018_00789_9 crossref_primary_10_1016_j_jad_2021_10_042 crossref_primary_10_1016_j_niox_2024_02_001 crossref_primary_10_1371_journal_pone_0294288 crossref_primary_10_1016_j_ajp_2017_02_016 crossref_primary_10_3389_fpsyt_2021_705749 crossref_primary_10_1016_j_pnpbp_2020_110136 crossref_primary_10_3390_molecules25225388 crossref_primary_10_2217_hep_2020_0028 crossref_primary_10_1016_j_neuropharm_2023_109568 crossref_primary_10_3390_ijerph15040771 crossref_primary_10_1515_revneuro_2016_0076 crossref_primary_10_1016_j_nicl_2023_103462 crossref_primary_10_1016_j_psyneuen_2021_105448 crossref_primary_10_1080_14737159_2018_1470927 crossref_primary_10_3389_fpsyt_2020_571636 crossref_primary_10_1097_HTR_0000000000000754 crossref_primary_10_3389_fimmu_2022_1032294 crossref_primary_10_1016_j_jad_2013_10_053 crossref_primary_10_1002_art_40565 crossref_primary_10_1016_j_psyneuen_2018_05_019 crossref_primary_10_1021_acs_jafc_0c02895 crossref_primary_10_1007_s11356_022_22662_0 crossref_primary_10_1007_s11524_018_00341_1 crossref_primary_10_1002_med_21666 crossref_primary_10_3389_fnhum_2020_585512 crossref_primary_10_3389_fimmu_2024_1332776 crossref_primary_10_1016_j_envres_2018_04_003 crossref_primary_10_1007_s00005_016_0441_7 crossref_primary_10_1017_S104161021600079X crossref_primary_10_1155_da_3131579 crossref_primary_10_3928_00485713_20150501_06 crossref_primary_10_1016_j_pnpbp_2017_08_024 crossref_primary_10_1038_s41598_018_34151_x crossref_primary_10_1038_ejcn_2017_61 crossref_primary_10_1080_13548506_2017_1339895 crossref_primary_10_1038_s41380_019_0471_8 crossref_primary_10_3390_biomedicines10071528 crossref_primary_10_1080_09513590_2017_1318367 crossref_primary_10_1371_journal_pone_0187448 crossref_primary_10_31083_j_jin2105143 crossref_primary_10_3390_ijerph15081705 crossref_primary_10_1016_j_pharmthera_2022_108293 crossref_primary_10_1017_S003329171800209X crossref_primary_10_1371_journal_pone_0111110 crossref_primary_10_1038_s41398_019_0671_7 crossref_primary_10_1007_s00213_019_05436_4 crossref_primary_10_1186_s12888_024_06359_x crossref_primary_10_3390_ijms24010479 crossref_primary_10_1007_s00586_018_5490_7 crossref_primary_10_1016_j_jneuroim_2018_02_011 crossref_primary_10_1016_j_smhs_2022_04_005 crossref_primary_10_1016_j_biomaterials_2023_122053 crossref_primary_10_1016_j_pbb_2013_10_026 crossref_primary_10_1371_journal_pone_0263519 crossref_primary_10_1016_j_bbi_2017_06_015 crossref_primary_10_1017_S0954579414001023 crossref_primary_10_1080_07853890_2024_2417179 crossref_primary_10_1093_aje_kwz180 crossref_primary_10_1016_j_expneurol_2019_112977 crossref_primary_10_1002_jcph_963 crossref_primary_10_4103_jrms_jrms_342_22 crossref_primary_10_1016_j_neubiorev_2013_03_018 crossref_primary_10_1038_s41598_017_03590_3 crossref_primary_10_1186_s12889_025_21726_3 crossref_primary_10_1016_j_jaim_2023_100767 crossref_primary_10_1016_j_yhbeh_2018_07_003 crossref_primary_10_1152_ajpheart_00615_2017 crossref_primary_10_1186_s12916_020_01749_w crossref_primary_10_1515_tjb_2019_0010 crossref_primary_10_3390_diseases8020023 crossref_primary_10_2174_0929867328666210922160116 crossref_primary_10_3389_fcvm_2023_1274595 crossref_primary_10_1007_s10802_016_0187_z crossref_primary_10_1007_s12640_017_9860_4 crossref_primary_10_1080_15622975_2017_1347713 crossref_primary_10_3390_nu16162721 crossref_primary_10_1097_QAI_0000000000000697 crossref_primary_10_1016_j_jad_2019_02_041 crossref_primary_10_1016_j_bbi_2023_12_012 crossref_primary_10_1093_aje_kwz190 crossref_primary_10_1007_s00127_014_0887_z crossref_primary_10_1007_s00406_021_01244_0 crossref_primary_10_1016_j_expneurol_2019_112969 crossref_primary_10_1038_s41398_024_03031_6 crossref_primary_10_3390_biomedicines12092116 crossref_primary_10_3389_fpsyt_2018_00037 crossref_primary_10_1016_j_cellsig_2022_110409 crossref_primary_10_3724_SP_J_1042_2019_00522 crossref_primary_10_2147_NDT_S247497 crossref_primary_10_1016_j_bbi_2019_09_016 crossref_primary_10_1093_pm_pnaa052 crossref_primary_10_1002_dev_21955 crossref_primary_10_1002_jnr_24312 crossref_primary_10_1016_j_psychres_2020_112782 crossref_primary_10_3390_ijms24010578 crossref_primary_10_1016_j_pbb_2020_172981 crossref_primary_10_3390_brainsci14121199 crossref_primary_10_1016_j_bbi_2018_07_006 crossref_primary_10_1016_j_envint_2021_106533 crossref_primary_10_30773_pi_2019_08_09 crossref_primary_10_1016_j_pnpbp_2012_07_016 crossref_primary_10_1038_tp_2015_155 crossref_primary_10_3389_fcimb_2022_1040211 crossref_primary_10_1371_journal_pone_0091076 crossref_primary_10_1016_j_neuroscience_2019_07_017 crossref_primary_10_1016_j_bbi_2019_02_014 crossref_primary_10_1016_j_jad_2022_09_062 crossref_primary_10_1038_s41386_018_0148_z crossref_primary_10_1097_WNF_0000000000000518 crossref_primary_10_1002_brb3_892 crossref_primary_10_1016_j_brainresbull_2024_111056 crossref_primary_10_1007_s10719_020_09916_0 crossref_primary_10_1016_j_physbeh_2019_112598 crossref_primary_10_1016_j_ctim_2018_06_008 crossref_primary_10_1186_s12877_024_04895_5 crossref_primary_10_1016_j_mehy_2015_10_001 crossref_primary_10_1016_j_neubiorev_2016_02_017 crossref_primary_10_1017_neu_2022_22 crossref_primary_10_1002_cncr_31538 crossref_primary_10_1007_s00127_020_01994_7 crossref_primary_10_1016_j_pnpbp_2013_09_017 crossref_primary_10_1136_bmjopen_2017_017173 crossref_primary_10_1016_j_bbi_2016_04_012 crossref_primary_10_1016_j_bbr_2021_113269 crossref_primary_10_1111_j_1600_0447_2012_01908_x crossref_primary_10_1176_appi_ajp_2015_15020152 crossref_primary_10_1007_s40263_017_0422_3 crossref_primary_10_1038_s41598_022_13562_x crossref_primary_10_1016_j_jpsychires_2013_10_015 crossref_primary_10_1891_1541_6577_32_4_400 crossref_primary_10_3389_fphar_2023_1257617 crossref_primary_10_3390_ijms18102226 crossref_primary_10_1038_s41398_020_00920_4 crossref_primary_10_1007_s11062_017_9615_0 crossref_primary_10_1016_j_bbi_2020_03_026 crossref_primary_10_1016_j_jad_2022_08_047 crossref_primary_10_1016_j_neulet_2015_08_025 crossref_primary_10_4000_pistes_4953 crossref_primary_10_4303_jdar_236036 crossref_primary_10_1038_tp_2015_137 crossref_primary_10_1093_neuonc_not321 crossref_primary_10_1371_journal_pone_0248454 crossref_primary_10_1016_j_bbi_2020_04_069 crossref_primary_10_1080_08039488_2023_2290654 crossref_primary_10_1080_15622975_2019_1612090 crossref_primary_10_1038_npp_2016_194 crossref_primary_10_1177_0300060520925943 crossref_primary_10_1016_j_bbih_2023_100689 crossref_primary_10_1017_S1368980018002525 crossref_primary_10_1016_j_euroneuro_2020_06_006 crossref_primary_10_2174_1568026620666200110161105 crossref_primary_10_1038_s41598_018_30487_6 crossref_primary_10_3390_cells10061423 crossref_primary_10_2174_1874196702008010029 crossref_primary_10_1016_j_mhp_2017_01_003 crossref_primary_10_1136_bmjopen_2020_046283 crossref_primary_10_7717_peerj_13480 crossref_primary_10_1016_j_neulet_2018_06_033 crossref_primary_10_1097_PSY_0000000000000051 crossref_primary_10_3389_fmed_2020_00039 crossref_primary_10_1055_a_1341_1907 crossref_primary_10_1016_j_euroneuro_2023_02_006 crossref_primary_10_1016_j_jad_2024_08_204 crossref_primary_10_1007_s00737_018_0855_9 crossref_primary_10_3389_fpsyt_2021_546801 crossref_primary_10_1016_j_anai_2020_03_023 crossref_primary_10_3390_healthcare5010005 crossref_primary_10_3389_fpsyg_2022_823420 crossref_primary_10_1016_j_bbi_2020_04_055 crossref_primary_10_1016_j_psychres_2016_04_049 crossref_primary_10_1007_s11481_013_9518_9 crossref_primary_10_1016_j_jneuroim_2015_08_011 crossref_primary_10_1016_j_euroneuro_2019_05_010 crossref_primary_10_1017_S0954579415000164 crossref_primary_10_1016_j_heliyon_2020_e03990 crossref_primary_10_1016_j_neuropharm_2015_09_019 crossref_primary_10_1016_j_jneuroim_2024_578372 crossref_primary_10_1186_s12888_024_05639_w crossref_primary_10_3389_fpsyt_2024_1283406 crossref_primary_10_1016_j_jaut_2019_102339 crossref_primary_10_1016_j_jad_2013_01_014 crossref_primary_10_1186_s12882_023_03291_2 crossref_primary_10_1016_j_bbi_2016_12_025 crossref_primary_10_1038_srep40530 crossref_primary_10_3390_life12020196 crossref_primary_10_3390_ijms21062194 crossref_primary_10_3389_fcell_2022_943067 crossref_primary_10_1186_s12889_023_15358_8 crossref_primary_10_3390_jpm13091395 crossref_primary_10_3758_s13415_019_00743_x crossref_primary_10_1016_j_neuron_2018_08_001 crossref_primary_10_1016_j_jad_2014_03_023 crossref_primary_10_1016_j_suc_2015_08_005 crossref_primary_10_1016_j_psychres_2018_08_078 crossref_primary_10_1016_j_ypmed_2021_106891 crossref_primary_10_1016_j_copsyc_2015_02_003 crossref_primary_10_1016_j_jad_2016_06_012 crossref_primary_10_1016_j_bbi_2024_09_003 crossref_primary_10_3389_fnins_2024_1366559 crossref_primary_10_1016_j_psychres_2017_05_029 crossref_primary_10_3233_NIB_180143 crossref_primary_10_1016_j_cpnec_2022_100131 crossref_primary_10_3390_ph13050092 crossref_primary_10_1016_j_arth_2016_01_063 crossref_primary_10_1016_j_arr_2023_101998 crossref_primary_10_3390_photonics10010090 crossref_primary_10_1016_j_ctrv_2016_11_004 crossref_primary_10_1038_npp_2016_169 crossref_primary_10_3390_ijerph17030689 crossref_primary_10_1016_j_bbi_2022_12_014 crossref_primary_10_1111_ejn_15181 crossref_primary_10_1016_j_jamda_2015_01_084 crossref_primary_10_1016_j_jad_2023_01_086 crossref_primary_10_1007_s00281_019_00730_x |
| Cites_doi | 10.1210/en.140.9.3890 10.1080/00048670601057759 10.1159/000054867 10.1176/ajp.150.8.1189 10.1016/1043-4666(92)90021-I 10.1152/ajpregu.00131.2010 10.1056/NEJM199505183322008 10.3390/medicina45120124 10.1159/000081248 10.1016/S0924-977X(01)00081-5 10.1016/S0022-3999(97)00139-6 10.1097/JGP.0b013e3181c2947f 10.1001/archpsyc.62.10.1097 10.1177/147323000303100106 10.1002/jnr.20531 10.1523/JNEUROSCI.2723-06.2006 10.1111/j.1600-0447.1998.tb10005.x 10.1016/j.pnpbp.2007.09.015 10.1016/0165-0327(95)00028-L 10.1160/TH08-07-0421 10.1016/j.biopsych.2009.09.033 10.1002/hep.1840130211 10.1159/000072221 10.1002/hup.717 10.1038/nrn2297 10.1037/h0031619 10.3109/10826080802490584 10.4088/JCP.v67n1114 10.1016/j.euroneuro.2008.08.001 10.1016/j.pnpbp.2010.06.014 10.1002/hup.1155 10.1016/0924-9338(96)80345-2 10.1016/j.jad.2005.07.008 10.1016/0024-3205(92)90112-3 10.1016/0262-1746(83)90048-3 10.1017/S0033291700032712 10.1016/j.bbi.2005.05.004 10.1016/0197-2456(86)90046-2 10.1016/j.tins.2008.06.006 10.1097/PSY.0b013e3181907c1b 10.1016/j.jpsychires.2010.02.008 10.1111/j.1460-9568.2007.05309.x 10.1097/01.psy.0000149259.72488.09 10.1159/000119472 10.1016/j.jpsychires.2006.05.013 10.1155/2007/76396 10.1016/0165-0327(94)90135-X 10.1016/j.biopsych.2005.10.013 10.1016/0165-0327(91)90060-6 10.1111/j.1440-1819.2007.01686.x 10.1111/j.1600-0447.1991.tb03163.x 10.1016/S0165-1781(96)02783-7 10.1016/j.jpsychires.2009.05.010 10.1128/AAC.38.1.7 10.1016/S0165-0327(02)00315-4 10.1016/0165-1781(94)90003-5 10.1007/BF02190412 10.1007/s00213-003-1566-z 10.1038/sj.mp.4000572 10.1176/ajp.151.1.112 10.1111/j.1749-6632.1995.tb44697.x 10.1016/0165-0327(92)90066-F 10.1016/j.brainres.2005.06.085 10.1016/j.euroneuro.2007.06.004 10.1006/cyto.1997.0238 10.2174/1381612053381684 10.1016/j.jneuroim.2005.08.014 |
| ContentType | Journal Article |
| Copyright | 2011 Elsevier B.V. Elsevier B.V. 2015 INIST-CNRS Copyright © 2011 Elsevier B.V. All rights reserved. |
| Copyright_xml | – notice: 2011 Elsevier B.V. – notice: Elsevier B.V. – notice: 2015 INIST-CNRS – notice: Copyright © 2011 Elsevier B.V. All rights reserved. |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 7QJ |
| DOI | 10.1016/j.jad.2011.08.003 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Applied Social Sciences Index & Abstracts (ASSIA) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic Applied Social Sciences Index and Abstracts (ASSIA) |
| DatabaseTitleList | MEDLINE - Academic Applied Social Sciences Index and Abstracts (ASSIA) Applied Social Sciences Index and Abstracts (ASSIA) MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 1573-2517 |
| EndPage | 239 |
| ExternalDocumentID | 21872339 26042790 10_1016_j_jad_2011_08_003 S0165032711004605 1_s2_0_S0165032711004605 |
| Genre | Meta-Analysis Journal Article |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29J 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAGKA AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABFNM ABIVO ABJNI ABLJU ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFS ACHQT ACIEU ACIUM ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADVLN AEBSH AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEG HMK HMO HMQ HMW HVGLF HZ~ IHE J1W KOM M29 M2V M39 M3V M41 MO0 N9A O-L O9- OAUVE OH0 OU- OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SNS SPCBC SPS SSH SSZ T5K UV1 WUQ Z5R ZGI ~G- 0SF AACTN AFCTW AFKWA AJOXV AMFUW NCXOZ RIG AAIAV ABLVK ABYKQ AJBFU EFLBG LCYCR ZA5 AAYXX AGRNS CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 ACLOT ~HD 7QJ |
| ID | FETCH-LOGICAL-c554t-4f09032de27d5b6914ad65d39e9a56cd81e72225e494a99bb7a851edb73101a93 |
| IEDL.DBID | .~1 |
| ISSN | 0165-0327 1573-2517 |
| IngestDate | Sun Sep 28 07:58:42 EDT 2025 Sun Sep 28 09:26:01 EDT 2025 Sun Sep 28 03:17:15 EDT 2025 Mon Jul 21 06:02:11 EDT 2025 Wed Apr 02 07:21:10 EDT 2025 Tue Jul 01 02:03:52 EDT 2025 Thu Apr 24 23:08:39 EDT 2025 Fri Feb 23 02:31:44 EST 2024 Mon Feb 24 20:22:41 EST 2025 Tue Aug 26 17:09:14 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | Meta-regression Depression Inflammation Cytokine Meta-analysis Mood disorder Human Regression Review Metaanalysis Interleukin 6 Interleukin 2 Tumor necrosis factor Tumor necrosis factor α Biological receptor |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 CC BY 4.0 Copyright © 2011 Elsevier B.V. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c554t-4f09032de27d5b6914ad65d39e9a56cd81e72225e494a99bb7a851edb73101a93 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 21872339 |
| PQID | 1020048869 |
| PQPubID | 24071 |
| PageCount | 10 |
| ParticipantIDs | proquest_miscellaneous_1761654078 proquest_miscellaneous_1038111583 proquest_miscellaneous_1020048869 pubmed_primary_21872339 pascalfrancis_primary_26042790 crossref_citationtrail_10_1016_j_jad_2011_08_003 crossref_primary_10_1016_j_jad_2011_08_003 elsevier_sciencedirect_doi_10_1016_j_jad_2011_08_003 elsevier_clinicalkeyesjournals_1_s2_0_S0165032711004605 elsevier_clinicalkey_doi_10_1016_j_jad_2011_08_003 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2012-08-01 |
| PublicationDateYYYYMMDD | 2012-08-01 |
| PublicationDate_xml | – month: 08 year: 2012 text: 2012-08-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Oxford |
| PublicationPlace_xml | – name: Oxford – name: Netherlands |
| PublicationTitle | Journal of affective disorders |
| PublicationTitleAlternate | J Affect Disord |
| PublicationYear | 2012 |
| Publisher | Elsevier B.V Elsevier |
| Publisher_xml | – name: Elsevier B.V – name: Elsevier |
| References | Eller, Aluoja, Maron, Vasar (bb0090) 2009; 45 Maes, Bosmans, Suy, Vandervorst, Dejonckheere, Raus (bb0180) 1991; 21 Song, Dinan, Leonard (bb0310) 1994; 30 Black (bb0025) 1994; 38 Basterzi, Aydemir, Kisa, Aksaray, Tuzer, Yazici, Goka (bb0015) 2005; 20 Simen, Duman, Simen, Duman (bb0290) 2006; 59 Vallieres, Rivest (bb0330) 1999; 140 Kubera, Kenis, Bosmans, Zieba, Dudek, Nowak, Maes (bb0145) 2000; 52 Dhabhar, Burke, Epel, Mellon, Rosser, Reus, Wolkowitz (bb0065) 2009; 43 Jozuka, Jozuka, Takeuchi, Nishikaze (bb0130) 2003; 31 McCann, Lyson, Karanth, Gimeno, Belova, Kamat, Rettori (bb0235) 1995; 771 Chrousos (bb0045) 1995; 332 Banks (bb0010) 2005; 11 Maes, Meltzer, Bosmans, Bergmans, Vandoolaeghe, Ranjan, Desnyder (bb0215) 1995; 34 Berk, Wadee, Kuschke, O'Neill-Kerr (bb0020) 1997; 43 Maes, Lambrechts, Bosmans, Jacobs, Suy, Vandervorst, de Jonckheere, Minner, Raus (bb0190) 1992; 22 Tuglu, Kara, Caliyurt, Vardar, Abay (bb0325) 2003; 170 Simon, McNamara, Chow, Maser, Papakostas, Pollack, Nierenberg, Fava, Wong (bb0295) 2008; 18 Sartorius (bb0285) 2001; 62 Maes, Bosmans, Suy, Vandervorst, DeJonckheere, Raus (bb0185) 1991; 84 Diniz, Teixeira, Talib, Gattaz, Forlenza (bb0070) 2010; 18 O'Brien, Scully, Fitzgerald, Scott, Dinan (bb0260) 2007; 41 Rehm, Rehn, Room, Monteiro, Gmel, Jernigan, Frick (bb0280) 2003; 9 Pariante, Lightman (bb0265) 2008; 31 Hasin, Goodwin, Stinson, Grant (bb0100) 2005; 62 Yang, Xie, Zhang, Wang, Li, Zhou, Tang (bb0345) 2007; 41 Adib-Conquy, Cavaillon (bb0005) 2009; 101 Maes, Meltzer, Buckley, Bosmans (bb0220) 1995; 244 Maes, Bosmans, De Jongh, Kenis, Vandoolaeghe, Neels (bb0230) 1997; 9 Liu, Lin, Tzeng (bb0160) 2005; 1054 Mikova, Yakimova, Bosmans, Kenis, Maes (bb0240) 2001; 11 Motivala, Sarfatti, Olmos, Irwin (bb0245) 2005; 67 Huang, Lee (bb0115) 2007; 61 Diniz, Teixeira, Talib, Mendonca, Gattaz, Forlenza (bb0075) 2010; 44 Pike, Irwin (bb0275) 2006; 20 Dowlati, Herrmann, Swardfager, Liu, Sham, Reim, Lanctot (bb0080) 2010; 67 Myint, Leonard, Steinbusch, Kim (bb0250) 2005; 88 Wei, Xu, Davies, Hemmings (bb0335) 1992; 51 Simopoulos (bb0300) 2004; 93 Maes, Bosmans, Suy, Vandervorst, De Jonckheere, Raus (bb0175) 1990–1991; 24 Hernandez, Mendieta, Martinez-Fong, Loria, Moreno, Estrada, Bojalil, Pavon (bb0105) 2008; 18 Eller, Vasar, Shlik, Maron (bb0085) 2008; 32 Tan, Lim, Leong, Lim, Lee, Yang, Tan, Winslow (bb0320) 2010; 45 Jankord, Zhang, Flak, Solomon, Albertz, Herman (bb0125) 2010; 299 Maes, Delanghe, Scharpé, Meltzer, Cosyns, Suy, Bosmans (bb0205) 1994; 151 Maes, Bosmans, Scharpé, D'Hondt, Desnyder (bb0225) 1995; 10 Sluzewska, Rybakowski, Bosmans, Sobieska, Berghmans, Maes, Wiktorowicz (bb0305) 1996; 64 DerSimonian, Laird (bb0060) 1986; 7 Lieb, Karmali, Horrobin (bb0155) 1983; 10 Dantzer, O'Connor, Freund, Johnson, Kelley (bb0055) 2008; 9 Fleiss (bb0095) 1971; 76 Nakanishi, Niidome, Matsuda, Akaike, Kihara, Sugimoto (bb0255) 2007; 25 Zangerle, De Groote, Lopez, Meuleman, Vrindts, Fauchet, Dehart, Jadoul, Radoux, Franchimont (bb0355) 1992; 4 Leo, Di Lorenzo, Tesauro, Razzini, Forleo, Chiricolo, Cola, Zanasi, Troisi, Siracusano, Lauro, Romeo (bb0150) 2006; 67 Maes (bb0170) 2011; 35 Pavon, Sandoval-Lopez, Eugenia Hernandez, Loria, Estrada, Perez, Moreno, Avila, Leff, Anton, Heinze (bb0270) 2006; 172 Cacci, Claasen, Kokaia (bb0040) 2005; 80 Iosif, Ekdahl, Ahlenius, Pronk, Bonde, Kokaia, Jacobsen, Lindvall (bb0120) 2006; 26 Sutcigil, Oktenli, Musabak, Bozkurt, Cansever, Uzun, Sanisoglu, Yesilova, Ozmenler, Ozsahin, Sengul (bb0315) 2007; 2007 Brambilla, Monteleone, Maj (bb0035) 2004; 78 Maes, Bosmans, Meltzer, Scharpé, Suy (bb0200) 1993; 150 Howren, Lamkin, Suls (bb0110) 2009; 71 Maes, Scharpé, Meltzer, Okayli, Bosmans, D'Hondt, Vanden Bossche, Cosyns (bb0210) 1994; 54 Yoshimura, Umene-Nakano, Hoshuyama, Ikenouchi-Sugita, Hori, Katsuki, Hayashi, Atake, Nakamura (bb0350) 2010; 25 Brambilla, Maggioni (bb0030) 1998; 97 Khoruts, Stahnke, McClain, Logan, Allen (bb0140) 1991; 13 Wells, Shea, O'Connell, Peterson, Welch, Losos (bb0340) 2009 Dantzer, Wollman, Vitkovic, Yirmiya (bb0050) 1999; 4 Maes, Scharpé, Van Grootel, Uyttenbroeck, Cooreman, Cosyns, Suy (bb0195) 1992; 24 Kagaya, Kugaya, Takebayashi, Fukue-Saeki, Saeki, Yamawaki, Uchitomi (bb0135) 2001; 43 Maes (bb0165) 1999 Hasin (10.1016/j.jad.2011.08.003_bb0100) 2005; 62 Brambilla (10.1016/j.jad.2011.08.003_bb0030) 1998; 97 Chrousos (10.1016/j.jad.2011.08.003_bb0045) 1995; 332 Leo (10.1016/j.jad.2011.08.003_bb0150) 2006; 67 Dowlati (10.1016/j.jad.2011.08.003_bb0080) 2010; 67 Dantzer (10.1016/j.jad.2011.08.003_bb0055) 2008; 9 Kagaya (10.1016/j.jad.2011.08.003_bb0135) 2001; 43 Sluzewska (10.1016/j.jad.2011.08.003_bb0305) 1996; 64 Dhabhar (10.1016/j.jad.2011.08.003_bb0065) 2009; 43 Yoshimura (10.1016/j.jad.2011.08.003_bb0350) 2010; 25 Maes (10.1016/j.jad.2011.08.003_bb0205) 1994; 151 Simen (10.1016/j.jad.2011.08.003_bb0290) 2006; 59 Maes (10.1016/j.jad.2011.08.003_bb0195) 1992; 24 Maes (10.1016/j.jad.2011.08.003_bb0170) 2011; 35 Eller (10.1016/j.jad.2011.08.003_bb0090) 2009; 45 O'Brien (10.1016/j.jad.2011.08.003_bb0260) 2007; 41 Myint (10.1016/j.jad.2011.08.003_bb0250) 2005; 88 Maes (10.1016/j.jad.2011.08.003_bb0225) 1995; 10 Khoruts (10.1016/j.jad.2011.08.003_bb0140) 1991; 13 Eller (10.1016/j.jad.2011.08.003_bb0085) 2008; 32 Brambilla (10.1016/j.jad.2011.08.003_bb0035) 2004; 78 Vallieres (10.1016/j.jad.2011.08.003_bb0330) 1999; 140 Adib-Conquy (10.1016/j.jad.2011.08.003_bb0005) 2009; 101 Basterzi (10.1016/j.jad.2011.08.003_bb0015) 2005; 20 Simopoulos (10.1016/j.jad.2011.08.003_bb0300) 2004; 93 Sutcigil (10.1016/j.jad.2011.08.003_bb0315) 2007; 2007 Jankord (10.1016/j.jad.2011.08.003_bb0125) 2010; 299 Pavon (10.1016/j.jad.2011.08.003_bb0270) 2006; 172 Pike (10.1016/j.jad.2011.08.003_bb0275) 2006; 20 Berk (10.1016/j.jad.2011.08.003_bb0020) 1997; 43 Diniz (10.1016/j.jad.2011.08.003_bb0070) 2010; 18 Wei (10.1016/j.jad.2011.08.003_bb0335) 1992; 51 Maes (10.1016/j.jad.2011.08.003_bb0220) 1995; 244 Kubera (10.1016/j.jad.2011.08.003_bb0145) 2000; 52 Maes (10.1016/j.jad.2011.08.003_bb0165) 1999 Maes (10.1016/j.jad.2011.08.003_bb0200) 1993; 150 Maes (10.1016/j.jad.2011.08.003_bb0185) 1991; 84 Mikova (10.1016/j.jad.2011.08.003_bb0240) 2001; 11 Maes (10.1016/j.jad.2011.08.003_bb0180) 1991; 21 Fleiss (10.1016/j.jad.2011.08.003_bb0095) 1971; 76 Sartorius (10.1016/j.jad.2011.08.003_bb0285) 2001; 62 Jozuka (10.1016/j.jad.2011.08.003_bb0130) 2003; 31 Motivala (10.1016/j.jad.2011.08.003_bb0245) 2005; 67 Hernandez (10.1016/j.jad.2011.08.003_bb0105) 2008; 18 Simon (10.1016/j.jad.2011.08.003_bb0295) 2008; 18 Tan (10.1016/j.jad.2011.08.003_bb0320) 2010; 45 Maes (10.1016/j.jad.2011.08.003_bb0175) 1990; 24 Song (10.1016/j.jad.2011.08.003_bb0310) 1994; 30 McCann (10.1016/j.jad.2011.08.003_bb0235) 1995; 771 Black (10.1016/j.jad.2011.08.003_bb0025) 1994; 38 DerSimonian (10.1016/j.jad.2011.08.003_bb0060) 1986; 7 Banks (10.1016/j.jad.2011.08.003_bb0010) 2005; 11 Tuglu (10.1016/j.jad.2011.08.003_bb0325) 2003; 170 Pariante (10.1016/j.jad.2011.08.003_bb0265) 2008; 31 Cacci (10.1016/j.jad.2011.08.003_bb0040) 2005; 80 Diniz (10.1016/j.jad.2011.08.003_bb0075) 2010; 44 Huang (10.1016/j.jad.2011.08.003_bb0115) 2007; 61 Liu (10.1016/j.jad.2011.08.003_bb0160) 2005; 1054 Maes (10.1016/j.jad.2011.08.003_bb0210) 1994; 54 Rehm (10.1016/j.jad.2011.08.003_bb0280) 2003; 9 Lieb (10.1016/j.jad.2011.08.003_bb0155) 1983; 10 Wells (10.1016/j.jad.2011.08.003_bb0340) Maes (10.1016/j.jad.2011.08.003_bb0190) 1992; 22 Zangerle (10.1016/j.jad.2011.08.003_bb0355) 1992; 4 Iosif (10.1016/j.jad.2011.08.003_bb0120) 2006; 26 Dantzer (10.1016/j.jad.2011.08.003_bb0050) 1999; 4 Nakanishi (10.1016/j.jad.2011.08.003_bb0255) 2007; 25 Yang (10.1016/j.jad.2011.08.003_bb0345) 2007; 41 Maes (10.1016/j.jad.2011.08.003_bb0215) 1995; 34 Maes (10.1016/j.jad.2011.08.003_bb0230) 1997; 9 Howren (10.1016/j.jad.2011.08.003_bb0110) 2009; 71 |
| References_xml | – volume: 43 start-page: 59 year: 2001 end-page: 62 ident: bb0135 article-title: Plasma concentrations of interleukin-1beta, interleukin-6, soluble interleukin-2 receptor and tumor necrosis factor alpha of depressed patients in Japan publication-title: Neuropsychobiology – volume: 41 start-page: 326 year: 2007 end-page: 331 ident: bb0260 article-title: Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy publication-title: J. Psychiatr. Res. – volume: 172 start-page: 156 year: 2006 end-page: 165 ident: bb0270 article-title: Th2 cytokine response in major depressive disorder patients before treatment publication-title: J. Neuroimmunol. – volume: 20 start-page: 473 year: 2005 end-page: 476 ident: bb0015 article-title: IL-6 levels decrease with SSRI treatment in patients with major depression publication-title: Hum. Psychopharmacol. – volume: 18 start-page: 172 year: 2010 end-page: 176 ident: bb0070 article-title: Interleukin-1beta serum levels is increased in antidepressant-free elderly depressed patients publication-title: Am. J. Geriatr. Psychiatry – volume: 2007 start-page: 76396 year: 2007 ident: bb0315 article-title: Pro- and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy publication-title: Clin. Dev. Immunol. – volume: 10 start-page: 361 year: 1983 end-page: 367 ident: bb0155 article-title: Elevated levels of prostaglandin E2 and thromboxane B2 in depression publication-title: Prostaglandins Leukot. Med. – volume: 9 start-page: 46 year: 2008 end-page: 56 ident: bb0055 article-title: From inflammation to sickness and depression: when the immune system subjugates the brain publication-title: Nat. Rev. Neurosci. – volume: 62 start-page: 8 year: 2001 end-page: 11 ident: bb0285 article-title: The economic and social burden of depression publication-title: J. Clin. Psychiatry – volume: 11 start-page: 203 year: 2001 end-page: 208 ident: bb0240 article-title: Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis publication-title: Eur. Neuropsychopharmacol. – volume: 170 start-page: 429 year: 2003 end-page: 433 ident: bb0325 article-title: Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder publication-title: Psychopharmacology (Berl) – volume: 11 start-page: 973 year: 2005 end-page: 984 ident: bb0010 article-title: Blood-brain barrier transport of cytokines: a mechanism for neuropathology publication-title: Curr. Pharm. Des. – volume: 150 start-page: 1189 year: 1993 end-page: 1193 ident: bb0200 article-title: Interleukin-1 beta: a putative mediator of HPA axis hyperactivity in major depression? publication-title: Am. J. Psychiatry – volume: 45 start-page: 1 year: 2010 end-page: 14 ident: bb0320 article-title: Alcohol and aldehyde dehydrogenase polymorphisms in Chinese and Indian populations publication-title: Subst. Use Misuse – volume: 32 start-page: 445 year: 2008 end-page: 450 ident: bb0085 article-title: Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder publication-title: Prog. Neuropsychopharmacol. Biol. Psychiatry – volume: 18 start-page: 917 year: 2008 end-page: 924 ident: bb0105 article-title: Variations in circulating cytokine levels during 52 publication-title: Eur. Neuropsychopharmacol. – volume: 244 start-page: 325 year: 1995 end-page: 329 ident: bb0220 article-title: Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression publication-title: Eur. Arch. Psychiatry Clin. Neurosci. – volume: 41 start-page: 266 year: 2007 end-page: 273 ident: bb0345 article-title: Levels of serum interleukin (IL)-6, IL-1beta, tumour necrosis factor-alpha and leptin and their correlation in depression publication-title: Aust. N. Z. J. Psychiatry – volume: 26 start-page: 9703 year: 2006 end-page: 9712 ident: bb0120 article-title: Tumor necrosis factor receptor 1 is a negative regulator of progenitor proliferation in adult hippocampal neurogenesis publication-title: J. Neurosci. – volume: 140 start-page: 3890 year: 1999 end-page: 3903 ident: bb0330 article-title: Interleukin-6 is a needed proinflammatory cytokine in the prolonged neural activity and transcriptional activation of corticotropin-releasing factor during endotoxemia publication-title: Endocrinology – volume: 332 start-page: 1351 year: 1995 end-page: 1362 ident: bb0045 article-title: The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation publication-title: N. Engl. J. Med. – volume: 9 start-page: 147 year: 2003 end-page: 156 ident: bb0280 article-title: The global distribution of average volume of alcohol consumption and patterns of drinking publication-title: Eur. Addict. Res. – volume: 45 start-page: 971 year: 2009 end-page: 977 ident: bb0090 article-title: Soluble interleukin-2 receptor and tumor necrosis factor levels in depressed patients in Estonia publication-title: Medicina (Kaunas) – volume: 67 start-page: 1760 year: 2006 end-page: 1766 ident: bb0150 article-title: Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: pilot observations on the effects of selective serotonin reuptake inhibitor therapy publication-title: J. Clin. Psychiatry – volume: 31 start-page: 464 year: 2008 end-page: 468 ident: bb0265 article-title: The HPA axis in major depression: classical theories and new developments publication-title: Trends Neurosci. – volume: 67 start-page: 446 year: 2010 end-page: 457 ident: bb0080 article-title: A meta-analysis of cytokines in major depression publication-title: Biol. Psychiatry – volume: 59 start-page: 775 year: 2006 end-page: 785 ident: bb0290 article-title: TNFalpha signaling in depression and anxiety: behavioral consequences of individual receptor targeting publication-title: Biol. Psychiatry – volume: 34 start-page: 301 year: 1995 end-page: 309 ident: bb0215 article-title: Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression publication-title: J. Affect. Disord. – volume: 43 start-page: 962 year: 2009 end-page: 969 ident: bb0065 article-title: Low serum IL-10 concentrations and loss of regulatory association between IL-6 and IL-10 in adults with major depression publication-title: J. Psychiatr. Res. – volume: 43 start-page: 529 year: 1997 end-page: 534 ident: bb0020 article-title: Acute phase proteins in major depression publication-title: J. Psychosom. Res. – volume: 151 start-page: 112 year: 1994 end-page: 116 ident: bb0205 article-title: Haptoglobin phenotypes and gene frequencies in unipolar major depression publication-title: Am. J. Psychiatry – volume: 31 start-page: 36 year: 2003 end-page: 41 ident: bb0130 article-title: Comparison of immunological and endocrinological markers associated with major depression publication-title: J. Int. Med. Res. – volume: 771 start-page: 386 year: 1995 end-page: 395 ident: bb0235 article-title: Mechanism of action of cytokines to induce the pattern of pituitary hormone secretion in infection publication-title: Ann. N. Y. Acad. Sci. – volume: 97 start-page: 309 year: 1998 end-page: 313 ident: bb0030 article-title: Blood levels of cytokines in elderly patients with major depressive disorder publication-title: Acta Psychiatr. Scand. – volume: 7 start-page: 177 year: 1986 end-page: 188 ident: bb0060 article-title: Meta-analysis in clinical trials publication-title: Control. Clin. Trials – volume: 76 start-page: 378 year: 1971 end-page: 382 ident: bb0095 article-title: Measuring nominal scale agreement among many raters publication-title: Psychol. Bull. – volume: 25 start-page: 566 year: 2010 end-page: 569 ident: bb0350 article-title: Plasma levels of brain-derived neurotrophic factor and interleukin-6 in patients with dysthymic disorder: comparison with age- and sex-matched major depressed patients and healthy controls publication-title: Hum. Psychopharmacol. – volume: 84 start-page: 379 year: 1991 end-page: 386 ident: bb0185 article-title: Depression-related disturbances in mitogen-induced lymphocyte responses and interleukin-1 beta and soluble interleukin-2 receptor production publication-title: Acta Psychiatr. Scand. – volume: 24 start-page: 115 year: 1990–1991 end-page: 120 ident: bb0175 article-title: Immune disturbances during major depression: upregulated expression of interleukin-2 receptors publication-title: Neuropsychobiology – volume: 52 start-page: 237 year: 2000 end-page: 241 ident: bb0145 article-title: Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor antagonist in depression: comparison between the acute state and after remission publication-title: Pol. J. Pharmacol. – volume: 35 start-page: 664 year: 2011 end-page: 675 ident: bb0170 article-title: Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression publication-title: Prog. Neuropsychopharmacol. Biol. Psychiatry – volume: 67 start-page: 187 year: 2005 end-page: 194 ident: bb0245 article-title: Inflammatory markers and sleep disturbance in major depression publication-title: Psychosom. Med. – volume: 20 start-page: 169 year: 2006 end-page: 174 ident: bb0275 article-title: Dissociation of inflammatory markers and natural killer cell activity in major depressive disorder publication-title: Brain Behav. Immun. – volume: 30 start-page: 283 year: 1994 end-page: 288 ident: bb0310 article-title: Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls publication-title: J. Affect. Disord. – volume: 51 start-page: 1953 year: 1992 end-page: 1956 ident: bb0335 article-title: Increase of plasma IL-6 concentraion with age in healthy subjects publication-title: Life Sci. – volume: 9 start-page: 853 year: 1997 end-page: 858 ident: bb0230 article-title: Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression publication-title: Cytokine – volume: 80 start-page: 789 year: 2005 end-page: 797 ident: bb0040 article-title: Microglia-derived tumor necrosis factor-alpha exaggerates death of newborn hippocampal progenitor cells in vitro publication-title: J. Neurosci. Res. – volume: 44 start-page: 917 year: 2010 end-page: 920 ident: bb0075 article-title: Increased soluble TNF receptor 2 in antidepressant-free patients with late-life depression publication-title: J. Psychiatr. Res. – volume: 13 start-page: 267 year: 1991 end-page: 276 ident: bb0140 article-title: Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients publication-title: Hepatology – volume: 24 start-page: 183 year: 1992 end-page: 192 ident: bb0195 article-title: Higher alpha 1-antitrypsin, haptoglobin, ceruloplasmin and lower retinol binding protein plasma levels during depression: further evidence for the existence of an inflammatory response during that illness publication-title: J. Affect. Disord. – volume: 61 start-page: 415 year: 2007 end-page: 420 ident: bb0115 article-title: T-helper 1/T-helper 2 cytokine imbalance and clinical phenotypes of acute-phase major depression publication-title: Psychiatry Clin. Neurosci. – start-page: 25 year: 1999 end-page: 46 ident: bb0165 article-title: Major depression and activation of the inflammatory response system publication-title: Cytokines, Stress and Depression – volume: 88 start-page: 167 year: 2005 end-page: 173 ident: bb0250 article-title: Th1, Th2, and Th3 cytokine alterations in major depression publication-title: J. Affect. Disord. – volume: 101 start-page: 36 year: 2009 end-page: 47 ident: bb0005 article-title: Compensatory anti-inflammatory response syndrome publication-title: Thromb. Haemost. – volume: 78 start-page: 273 year: 2004 end-page: 277 ident: bb0035 article-title: Interleukin-1beta and tumor necrosis factor-alpha in children with major depressive disorder or dysthymia publication-title: J. Affect. Disord. – volume: 4 start-page: 328 year: 1999 end-page: 332 ident: bb0050 article-title: Cytokines and depression: fortuitous or causative association? publication-title: Mol. Psychiatry – volume: 64 start-page: 161 year: 1996 end-page: 167 ident: bb0305 article-title: Indicators of immune activation in major depression publication-title: Psychiatry Res. – volume: 38 start-page: 7 year: 1994 end-page: 12 ident: bb0025 article-title: Immune system-central nervous system interactions: effect and immunomodulatory consequences of immune system mediators on the brain publication-title: Antimicrob. Agents Chemother. – volume: 18 start-page: 230 year: 2008 end-page: 233 ident: bb0295 article-title: A detailed examination of cytokine abnormalities in major depressive disorder publication-title: Eur. Neuropsychopharmacol. – volume: 62 start-page: 1097 year: 2005 end-page: 1106 ident: bb0100 article-title: Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions publication-title: Arch. Gen. Psychiatry – volume: 4 start-page: 568 year: 1992 end-page: 575 ident: bb0355 article-title: Direct stimulation of cytokines (IL-1 beta, TNF-alpha, IL-6, IL-2, IFN-gamma and GM-CSF) in whole blood: II. Application to rheumatoid arthritis and osteoarthritis publication-title: Cytokine – volume: 22 start-page: 45 year: 1992 end-page: 53 ident: bb0190 article-title: Evidence for a systemic immune activation during depression: results of leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody staining publication-title: Psychol. Med. – volume: 71 start-page: 171 year: 2009 end-page: 186 ident: bb0110 article-title: Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis publication-title: Psychosom. Med. – volume: 93 start-page: 1 year: 2004 end-page: 28 ident: bb0300 article-title: Genetic variation: nutritional implications publication-title: World Rev. Nutr. Diet. – volume: 299 start-page: R343 year: 2010 end-page: R351 ident: bb0125 article-title: Stress activation of IL-6 neurons in the hypothalamus publication-title: Am. J. Physiol. Regul. Integr. Comp. Physiol. – year: 2009 ident: bb0340 article-title: The Newcastle–Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses – volume: 1054 start-page: 152 year: 2005 end-page: 158 ident: bb0160 article-title: Tumor necrosis factor-alpha and interleukin-18 modulate neuronal cell fate in embryonic neural progenitor culture publication-title: Brain Res. – volume: 25 start-page: 649 year: 2007 end-page: 658 ident: bb0255 article-title: Microglia-derived interleukin-6 and leukaemia inhibitory factor promote astrocytic differentiation of neural stem/progenitor cells publication-title: Eur. J. Neurosci. – volume: 54 start-page: 143 year: 1994 end-page: 160 ident: bb0210 article-title: Increased neopterin and interferon-gamma secretion and lower availability of publication-title: Psychiatry Res. – volume: 10 start-page: 397 year: 1995 end-page: 403 ident: bb0225 article-title: Plasma soluble interleukin-2-receptor in depression: relationships to plasma neopterin and serum IL-2 concentrations and HPA-axis activity publication-title: Eur. Psychiatry – volume: 21 start-page: 133 year: 1991 end-page: 140 ident: bb0180 article-title: Antiphospholipid, antinuclear, Epstein–Barr and cytomegalovirus antibodies, and soluble interleukin-2 receptors in depressive patients publication-title: J. Affect. Disord. – volume: 140 start-page: 3890 year: 1999 ident: 10.1016/j.jad.2011.08.003_bb0330 article-title: Interleukin-6 is a needed proinflammatory cytokine in the prolonged neural activity and transcriptional activation of corticotropin-releasing factor during endotoxemia publication-title: Endocrinology doi: 10.1210/en.140.9.3890 – volume: 41 start-page: 266 year: 2007 ident: 10.1016/j.jad.2011.08.003_bb0345 article-title: Levels of serum interleukin (IL)-6, IL-1beta, tumour necrosis factor-alpha and leptin and their correlation in depression publication-title: Aust. N. Z. J. Psychiatry doi: 10.1080/00048670601057759 – volume: 43 start-page: 59 year: 2001 ident: 10.1016/j.jad.2011.08.003_bb0135 article-title: Plasma concentrations of interleukin-1beta, interleukin-6, soluble interleukin-2 receptor and tumor necrosis factor alpha of depressed patients in Japan publication-title: Neuropsychobiology doi: 10.1159/000054867 – volume: 150 start-page: 1189 year: 1993 ident: 10.1016/j.jad.2011.08.003_bb0200 article-title: Interleukin-1 beta: a putative mediator of HPA axis hyperactivity in major depression? publication-title: Am. J. Psychiatry doi: 10.1176/ajp.150.8.1189 – volume: 4 start-page: 568 year: 1992 ident: 10.1016/j.jad.2011.08.003_bb0355 article-title: Direct stimulation of cytokines (IL-1 beta, TNF-alpha, IL-6, IL-2, IFN-gamma and GM-CSF) in whole blood: II. Application to rheumatoid arthritis and osteoarthritis publication-title: Cytokine doi: 10.1016/1043-4666(92)90021-I – volume: 299 start-page: R343 year: 2010 ident: 10.1016/j.jad.2011.08.003_bb0125 article-title: Stress activation of IL-6 neurons in the hypothalamus publication-title: Am. J. Physiol. Regul. Integr. Comp. Physiol. doi: 10.1152/ajpregu.00131.2010 – volume: 332 start-page: 1351 year: 1995 ident: 10.1016/j.jad.2011.08.003_bb0045 article-title: The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation publication-title: N. Engl. J. Med. doi: 10.1056/NEJM199505183322008 – volume: 45 start-page: 971 year: 2009 ident: 10.1016/j.jad.2011.08.003_bb0090 article-title: Soluble interleukin-2 receptor and tumor necrosis factor levels in depressed patients in Estonia publication-title: Medicina (Kaunas) doi: 10.3390/medicina45120124 – volume: 93 start-page: 1 year: 2004 ident: 10.1016/j.jad.2011.08.003_bb0300 article-title: Genetic variation: nutritional implications publication-title: World Rev. Nutr. Diet. doi: 10.1159/000081248 – volume: 11 start-page: 203 year: 2001 ident: 10.1016/j.jad.2011.08.003_bb0240 article-title: Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis publication-title: Eur. Neuropsychopharmacol. doi: 10.1016/S0924-977X(01)00081-5 – volume: 43 start-page: 529 year: 1997 ident: 10.1016/j.jad.2011.08.003_bb0020 article-title: Acute phase proteins in major depression publication-title: J. Psychosom. Res. doi: 10.1016/S0022-3999(97)00139-6 – volume: 18 start-page: 172 year: 2010 ident: 10.1016/j.jad.2011.08.003_bb0070 article-title: Interleukin-1beta serum levels is increased in antidepressant-free elderly depressed patients publication-title: Am. J. Geriatr. Psychiatry doi: 10.1097/JGP.0b013e3181c2947f – volume: 62 start-page: 1097 year: 2005 ident: 10.1016/j.jad.2011.08.003_bb0100 article-title: Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions publication-title: Arch. Gen. Psychiatry doi: 10.1001/archpsyc.62.10.1097 – volume: 31 start-page: 36 year: 2003 ident: 10.1016/j.jad.2011.08.003_bb0130 article-title: Comparison of immunological and endocrinological markers associated with major depression publication-title: J. Int. Med. Res. doi: 10.1177/147323000303100106 – volume: 80 start-page: 789 year: 2005 ident: 10.1016/j.jad.2011.08.003_bb0040 article-title: Microglia-derived tumor necrosis factor-alpha exaggerates death of newborn hippocampal progenitor cells in vitro publication-title: J. Neurosci. Res. doi: 10.1002/jnr.20531 – volume: 26 start-page: 9703 year: 2006 ident: 10.1016/j.jad.2011.08.003_bb0120 article-title: Tumor necrosis factor receptor 1 is a negative regulator of progenitor proliferation in adult hippocampal neurogenesis publication-title: J. Neurosci. doi: 10.1523/JNEUROSCI.2723-06.2006 – volume: 97 start-page: 309 year: 1998 ident: 10.1016/j.jad.2011.08.003_bb0030 article-title: Blood levels of cytokines in elderly patients with major depressive disorder publication-title: Acta Psychiatr. Scand. doi: 10.1111/j.1600-0447.1998.tb10005.x – volume: 32 start-page: 445 year: 2008 ident: 10.1016/j.jad.2011.08.003_bb0085 article-title: Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder publication-title: Prog. Neuropsychopharmacol. Biol. Psychiatry doi: 10.1016/j.pnpbp.2007.09.015 – volume: 34 start-page: 301 year: 1995 ident: 10.1016/j.jad.2011.08.003_bb0215 article-title: Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression publication-title: J. Affect. Disord. doi: 10.1016/0165-0327(95)00028-L – volume: 101 start-page: 36 year: 2009 ident: 10.1016/j.jad.2011.08.003_bb0005 article-title: Compensatory anti-inflammatory response syndrome publication-title: Thromb. Haemost. doi: 10.1160/TH08-07-0421 – volume: 67 start-page: 446 year: 2010 ident: 10.1016/j.jad.2011.08.003_bb0080 article-title: A meta-analysis of cytokines in major depression publication-title: Biol. Psychiatry doi: 10.1016/j.biopsych.2009.09.033 – volume: 13 start-page: 267 year: 1991 ident: 10.1016/j.jad.2011.08.003_bb0140 article-title: Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients publication-title: Hepatology doi: 10.1002/hep.1840130211 – volume: 9 start-page: 147 year: 2003 ident: 10.1016/j.jad.2011.08.003_bb0280 article-title: The global distribution of average volume of alcohol consumption and patterns of drinking publication-title: Eur. Addict. Res. doi: 10.1159/000072221 – volume: 20 start-page: 473 year: 2005 ident: 10.1016/j.jad.2011.08.003_bb0015 article-title: IL-6 levels decrease with SSRI treatment in patients with major depression publication-title: Hum. Psychopharmacol. doi: 10.1002/hup.717 – volume: 9 start-page: 46 year: 2008 ident: 10.1016/j.jad.2011.08.003_bb0055 article-title: From inflammation to sickness and depression: when the immune system subjugates the brain publication-title: Nat. Rev. Neurosci. doi: 10.1038/nrn2297 – volume: 76 start-page: 378 year: 1971 ident: 10.1016/j.jad.2011.08.003_bb0095 article-title: Measuring nominal scale agreement among many raters publication-title: Psychol. Bull. doi: 10.1037/h0031619 – volume: 45 start-page: 1 year: 2010 ident: 10.1016/j.jad.2011.08.003_bb0320 article-title: Alcohol and aldehyde dehydrogenase polymorphisms in Chinese and Indian populations publication-title: Subst. Use Misuse doi: 10.3109/10826080802490584 – volume: 67 start-page: 1760 year: 2006 ident: 10.1016/j.jad.2011.08.003_bb0150 article-title: Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: pilot observations on the effects of selective serotonin reuptake inhibitor therapy publication-title: J. Clin. Psychiatry doi: 10.4088/JCP.v67n1114 – volume: 18 start-page: 917 year: 2008 ident: 10.1016/j.jad.2011.08.003_bb0105 article-title: Variations in circulating cytokine levels during 52week course of treatment with SSRI for major depressive disorder publication-title: Eur. Neuropsychopharmacol. doi: 10.1016/j.euroneuro.2008.08.001 – volume: 35 start-page: 664 year: 2011 ident: 10.1016/j.jad.2011.08.003_bb0170 article-title: Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression publication-title: Prog. Neuropsychopharmacol. Biol. Psychiatry doi: 10.1016/j.pnpbp.2010.06.014 – volume: 52 start-page: 237 year: 2000 ident: 10.1016/j.jad.2011.08.003_bb0145 article-title: Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor antagonist in depression: comparison between the acute state and after remission publication-title: Pol. J. Pharmacol. – volume: 25 start-page: 566 year: 2010 ident: 10.1016/j.jad.2011.08.003_bb0350 article-title: Plasma levels of brain-derived neurotrophic factor and interleukin-6 in patients with dysthymic disorder: comparison with age- and sex-matched major depressed patients and healthy controls publication-title: Hum. Psychopharmacol. doi: 10.1002/hup.1155 – volume: 10 start-page: 397 year: 1995 ident: 10.1016/j.jad.2011.08.003_bb0225 article-title: Plasma soluble interleukin-2-receptor in depression: relationships to plasma neopterin and serum IL-2 concentrations and HPA-axis activity publication-title: Eur. Psychiatry doi: 10.1016/0924-9338(96)80345-2 – volume: 62 start-page: 8 year: 2001 ident: 10.1016/j.jad.2011.08.003_bb0285 article-title: The economic and social burden of depression publication-title: J. Clin. Psychiatry – volume: 88 start-page: 167 year: 2005 ident: 10.1016/j.jad.2011.08.003_bb0250 article-title: Th1, Th2, and Th3 cytokine alterations in major depression publication-title: J. Affect. Disord. doi: 10.1016/j.jad.2005.07.008 – volume: 51 start-page: 1953 year: 1992 ident: 10.1016/j.jad.2011.08.003_bb0335 article-title: Increase of plasma IL-6 concentraion with age in healthy subjects publication-title: Life Sci. doi: 10.1016/0024-3205(92)90112-3 – volume: 10 start-page: 361 year: 1983 ident: 10.1016/j.jad.2011.08.003_bb0155 article-title: Elevated levels of prostaglandin E2 and thromboxane B2 in depression publication-title: Prostaglandins Leukot. Med. doi: 10.1016/0262-1746(83)90048-3 – volume: 22 start-page: 45 year: 1992 ident: 10.1016/j.jad.2011.08.003_bb0190 article-title: Evidence for a systemic immune activation during depression: results of leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody staining publication-title: Psychol. Med. doi: 10.1017/S0033291700032712 – volume: 20 start-page: 169 year: 2006 ident: 10.1016/j.jad.2011.08.003_bb0275 article-title: Dissociation of inflammatory markers and natural killer cell activity in major depressive disorder publication-title: Brain Behav. Immun. doi: 10.1016/j.bbi.2005.05.004 – volume: 7 start-page: 177 year: 1986 ident: 10.1016/j.jad.2011.08.003_bb0060 article-title: Meta-analysis in clinical trials publication-title: Control. Clin. Trials doi: 10.1016/0197-2456(86)90046-2 – volume: 31 start-page: 464 year: 2008 ident: 10.1016/j.jad.2011.08.003_bb0265 article-title: The HPA axis in major depression: classical theories and new developments publication-title: Trends Neurosci. doi: 10.1016/j.tins.2008.06.006 – volume: 71 start-page: 171 year: 2009 ident: 10.1016/j.jad.2011.08.003_bb0110 article-title: Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis publication-title: Psychosom. Med. doi: 10.1097/PSY.0b013e3181907c1b – volume: 44 start-page: 917 year: 2010 ident: 10.1016/j.jad.2011.08.003_bb0075 article-title: Increased soluble TNF receptor 2 in antidepressant-free patients with late-life depression publication-title: J. Psychiatr. Res. doi: 10.1016/j.jpsychires.2010.02.008 – volume: 25 start-page: 649 year: 2007 ident: 10.1016/j.jad.2011.08.003_bb0255 article-title: Microglia-derived interleukin-6 and leukaemia inhibitory factor promote astrocytic differentiation of neural stem/progenitor cells publication-title: Eur. J. Neurosci. doi: 10.1111/j.1460-9568.2007.05309.x – volume: 67 start-page: 187 year: 2005 ident: 10.1016/j.jad.2011.08.003_bb0245 article-title: Inflammatory markers and sleep disturbance in major depression publication-title: Psychosom. Med. doi: 10.1097/01.psy.0000149259.72488.09 – volume: 24 start-page: 115 year: 1990 ident: 10.1016/j.jad.2011.08.003_bb0175 article-title: Immune disturbances during major depression: upregulated expression of interleukin-2 receptors publication-title: Neuropsychobiology doi: 10.1159/000119472 – volume: 41 start-page: 326 year: 2007 ident: 10.1016/j.jad.2011.08.003_bb0260 article-title: Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy publication-title: J. Psychiatr. Res. doi: 10.1016/j.jpsychires.2006.05.013 – volume: 2007 start-page: 76396 year: 2007 ident: 10.1016/j.jad.2011.08.003_bb0315 article-title: Pro- and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy publication-title: Clin. Dev. Immunol. doi: 10.1155/2007/76396 – volume: 30 start-page: 283 year: 1994 ident: 10.1016/j.jad.2011.08.003_bb0310 article-title: Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls publication-title: J. Affect. Disord. doi: 10.1016/0165-0327(94)90135-X – volume: 59 start-page: 775 year: 2006 ident: 10.1016/j.jad.2011.08.003_bb0290 article-title: TNFalpha signaling in depression and anxiety: behavioral consequences of individual receptor targeting publication-title: Biol. Psychiatry doi: 10.1016/j.biopsych.2005.10.013 – volume: 21 start-page: 133 year: 1991 ident: 10.1016/j.jad.2011.08.003_bb0180 article-title: Antiphospholipid, antinuclear, Epstein–Barr and cytomegalovirus antibodies, and soluble interleukin-2 receptors in depressive patients publication-title: J. Affect. Disord. doi: 10.1016/0165-0327(91)90060-6 – volume: 61 start-page: 415 year: 2007 ident: 10.1016/j.jad.2011.08.003_bb0115 article-title: T-helper 1/T-helper 2 cytokine imbalance and clinical phenotypes of acute-phase major depression publication-title: Psychiatry Clin. Neurosci. doi: 10.1111/j.1440-1819.2007.01686.x – volume: 84 start-page: 379 year: 1991 ident: 10.1016/j.jad.2011.08.003_bb0185 article-title: Depression-related disturbances in mitogen-induced lymphocyte responses and interleukin-1 beta and soluble interleukin-2 receptor production publication-title: Acta Psychiatr. Scand. doi: 10.1111/j.1600-0447.1991.tb03163.x – ident: 10.1016/j.jad.2011.08.003_bb0340 – volume: 64 start-page: 161 year: 1996 ident: 10.1016/j.jad.2011.08.003_bb0305 article-title: Indicators of immune activation in major depression publication-title: Psychiatry Res. doi: 10.1016/S0165-1781(96)02783-7 – volume: 43 start-page: 962 year: 2009 ident: 10.1016/j.jad.2011.08.003_bb0065 article-title: Low serum IL-10 concentrations and loss of regulatory association between IL-6 and IL-10 in adults with major depression publication-title: J. Psychiatr. Res. doi: 10.1016/j.jpsychires.2009.05.010 – volume: 38 start-page: 7 year: 1994 ident: 10.1016/j.jad.2011.08.003_bb0025 article-title: Immune system-central nervous system interactions: effect and immunomodulatory consequences of immune system mediators on the brain publication-title: Antimicrob. Agents Chemother. doi: 10.1128/AAC.38.1.7 – volume: 78 start-page: 273 year: 2004 ident: 10.1016/j.jad.2011.08.003_bb0035 article-title: Interleukin-1beta and tumor necrosis factor-alpha in children with major depressive disorder or dysthymia publication-title: J. Affect. Disord. doi: 10.1016/S0165-0327(02)00315-4 – volume: 54 start-page: 143 year: 1994 ident: 10.1016/j.jad.2011.08.003_bb0210 article-title: Increased neopterin and interferon-gamma secretion and lower availability of l-tryptophan in major depression: further evidence for an immune response publication-title: Psychiatry Res. doi: 10.1016/0165-1781(94)90003-5 – volume: 244 start-page: 325 year: 1995 ident: 10.1016/j.jad.2011.08.003_bb0220 article-title: Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression publication-title: Eur. Arch. Psychiatry Clin. Neurosci. doi: 10.1007/BF02190412 – volume: 170 start-page: 429 year: 2003 ident: 10.1016/j.jad.2011.08.003_bb0325 article-title: Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder publication-title: Psychopharmacology (Berl) doi: 10.1007/s00213-003-1566-z – volume: 4 start-page: 328 year: 1999 ident: 10.1016/j.jad.2011.08.003_bb0050 article-title: Cytokines and depression: fortuitous or causative association? publication-title: Mol. Psychiatry doi: 10.1038/sj.mp.4000572 – volume: 151 start-page: 112 year: 1994 ident: 10.1016/j.jad.2011.08.003_bb0205 article-title: Haptoglobin phenotypes and gene frequencies in unipolar major depression publication-title: Am. J. Psychiatry doi: 10.1176/ajp.151.1.112 – volume: 771 start-page: 386 year: 1995 ident: 10.1016/j.jad.2011.08.003_bb0235 article-title: Mechanism of action of cytokines to induce the pattern of pituitary hormone secretion in infection publication-title: Ann. N. Y. Acad. Sci. doi: 10.1111/j.1749-6632.1995.tb44697.x – start-page: 25 year: 1999 ident: 10.1016/j.jad.2011.08.003_bb0165 article-title: Major depression and activation of the inflammatory response system – volume: 24 start-page: 183 year: 1992 ident: 10.1016/j.jad.2011.08.003_bb0195 article-title: Higher alpha 1-antitrypsin, haptoglobin, ceruloplasmin and lower retinol binding protein plasma levels during depression: further evidence for the existence of an inflammatory response during that illness publication-title: J. Affect. Disord. doi: 10.1016/0165-0327(92)90066-F – volume: 1054 start-page: 152 year: 2005 ident: 10.1016/j.jad.2011.08.003_bb0160 article-title: Tumor necrosis factor-alpha and interleukin-18 modulate neuronal cell fate in embryonic neural progenitor culture publication-title: Brain Res. doi: 10.1016/j.brainres.2005.06.085 – volume: 18 start-page: 230 year: 2008 ident: 10.1016/j.jad.2011.08.003_bb0295 article-title: A detailed examination of cytokine abnormalities in major depressive disorder publication-title: Eur. Neuropsychopharmacol. doi: 10.1016/j.euroneuro.2007.06.004 – volume: 9 start-page: 853 year: 1997 ident: 10.1016/j.jad.2011.08.003_bb0230 article-title: Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression publication-title: Cytokine doi: 10.1006/cyto.1997.0238 – volume: 11 start-page: 973 year: 2005 ident: 10.1016/j.jad.2011.08.003_bb0010 article-title: Blood-brain barrier transport of cytokines: a mechanism for neuropathology publication-title: Curr. Pharm. Des. doi: 10.2174/1381612053381684 – volume: 172 start-page: 156 year: 2006 ident: 10.1016/j.jad.2011.08.003_bb0270 article-title: Th2 cytokine response in major depressive disorder patients before treatment publication-title: J. Neuroimmunol. doi: 10.1016/j.jneuroim.2005.08.014 |
| SSID | ssj0006970 |
| Score | 2.5934184 |
| SecondaryResourceType | review_article |
| Snippet | Many studies have explored the association between soluble interleukin-2 receptor (sIL-2R), cytokines and major depressive disorder (MDD). However, the results... AbstractBackgroundMany studies have explored the association between soluble interleukin-2 receptor (sIL-2R), cytokines and major depressive disorder (MDD).... Background: Many studies have explored the association between soluble interleukin-2 receptor (sIL-2R), cytokines and major depressive disorder (MDD). However,... |
| SourceID | proquest pubmed pascalfrancis crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 230 |
| SubjectTerms | Accounting Adolescent Adult Adult and adolescent clinical studies Aged Biological and medical sciences Blood Child Cytokine Cytokines - blood Depression Depressive Disorder, Major - blood Depressive Disorder, Major - immunology Depressive personality disorders Female Heterogeneity Humans Inflammation Interleukin-6 - blood Logistic Models Male Medical sciences Meta-analysis Meta-regression Middle Aged Moderators Mood disorders Psychiatric/Mental Health Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Receptors, Interleukin-2 - analysis Receptors, Interleukin-2 - blood Sensitivity analysis Tumor Necrosis Factor-alpha - analysis Young Adult |
| Title | Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: A meta-analysis and meta-regression |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0165032711004605 https://www.clinicalkey.es/playcontent/1-s2.0-S0165032711004605 https://dx.doi.org/10.1016/j.jad.2011.08.003 https://www.ncbi.nlm.nih.gov/pubmed/21872339 https://www.proquest.com/docview/1020048869 https://www.proquest.com/docview/1038111583 https://www.proquest.com/docview/1761654078 |
| Volume | 139 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier) customDbUrl: eissn: 1573-2517 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0006970 issn: 0165-0327 databaseCode: GBLVA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Complete Freedom Collection (subscription) customDbUrl: eissn: 1573-2517 dateEnd: 20141231 omitProxy: true ssIdentifier: ssj0006970 issn: 0165-0327 databaseCode: ACRLP dateStart: 19950111 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals [SCFCJ] customDbUrl: eissn: 1573-2517 dateEnd: 20141231 omitProxy: true ssIdentifier: ssj0006970 issn: 0165-0327 databaseCode: AIKHN dateStart: 19950111 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Science Direct customDbUrl: eissn: 1573-2517 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0006970 issn: 0165-0327 databaseCode: .~1 dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1573-2517 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0006970 issn: 0165-0327 databaseCode: AKRWK dateStart: 19790301 isFulltext: true providerName: Library Specific Holdings |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NjtMwELZWywUJIRB_5acyEocuwjSxk7jmVq2oWrr0sOyKvVlOPEEt3WzVpBx5J56BO8_E2ElarRaKxClKNBM79mQ8Y898Q8grriAGLnLmsFxYlEHOUi6ApbiYxjZSocnchv7HWTI-jz5cxBcH5LjNhXFhlY3ur3W619bNk34zmv3VfN7_5BJxAsGlBz1LPI6pQ_9CmX77fRfmkShfMM4RM0fdnmz6GK-FsTsUz7Zu1s216c7KlDhieV3q4u-2qF-TRvfI3caYpMO6v_fJARQPyE-_ybeEzdd5QXuTkyOWvKHVBl38NS3AtTwvaV1mh_pMW9o7m43Yrx9H1BSWOllMl0Dnu7cwTnGMYOUK89BeOTlh_BSJ10BdcjoaqxapaYPQWlK3tUsvzQLf38bZfgNqG5jPd3RIL6EyzDRwKL5V_2QNX-qo3OIhOR-9Pzses6ZUA8vQHqlYlLv9Hm6BSxuniQojY5PYCgXKxElmByFI51lCpCKjVJpKg6Ye2FSieRkaJR6Rw-KqgCeE8pjHmUC3yJo0UkIZ4InkeS4DDg7Nr0OCdpJ01uCYu3IaS90GrC00zqt286pdic0AWV5vWVY1iMc-Yt7OvG6zU1Gfalxi9jHJPzFB2WiEUoe65DrQN6S2Q6It5zXB_1eD3WtCuf0u9E8jLlXQIS9bKdWoMdwxkCngaoM9CbjX24naR4OWHDoLA7GHRiYuFQ5tzA55XP8Gu16EA8mFUE__7-uekdt4x-tAy-fksFpv4AUaf1Xa9X93l9waTqbjmbtOTz9PfwPonFmC |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1fb9MwELem7gEkhED8K4NhJB46hNXEceKat2qialnXB-ikvVlOfEEtXVY17b4Xn4F3PhPnxGk1DYrEq3NnO_blfOfc_Y6Qd1xBDDzKmcNyYSKDnKU8ApbiYRpboUKTuQv980kyvBCfL-PLA3La5MK4sEqv-2udXmlr39L1q9ldzmbdry4RJ4i4rEDPEodjeihi1MktctgfnQ0nW4WcqKpmnKNnjqH5uVmFec2N3QF5NqWz7h5PD5amxEXL62oXfzdHq2Np8Ig89PYk7ddTfkwOoHhCflb3fAvYfJ8VtDMan7DkA11v0Mtf0QLcyLOS1pV2aJVsSzvTyYD9-nFCTWGpE8d0AXS264VxissES1ebh3bK0ZjxL0i8Aury09FetUhNPUhrSd3tLr0yc-y_CbW9AWo90udH2qdXsDbMeESUatSqZQXf6sDc4im5GHyang6Zr9bAMjRJ1kzk7sqHW-DSxmmiQmFsEttIgTJxktleCNI5lyCUMEqlqTRo7YFNJVqYoVHRM9Iqrgt4QSiPeZxF6BlZkwoVKQM8kTzPZcDBAfq1SdBsks48lLmrqLHQTczaXOO-arev2lXZDJDl_ZZlWeN47CPmzc7rJkEVVarGU2Yfk_wTE5ReKZQ61CXXgb4juG0itpy3ZP9fAx7fEsrte6GLKrhUQZu8baRUo9Jwf4JMAdcbnEnAK9WdqH00aMyhv9CL9tDIxGXDoZnZJs_rz2A3i7AneRSpl__3dm_IveH0fKzHo8nZEbmPT3gdd_mKtNarDbxGW3CdHvtv_TepX1qK |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Interleukin+%28IL%29-6%2C+tumour+necrosis+factor+alpha+%28TNF-%CE%B1%29+and+soluble+interleukin-2+receptors+%28sIL-2R%29+are+elevated+in+patients+with+major+depressive+disorder%3A+A+meta-analysis+and+meta-regression&rft.jtitle=Journal+of+affective+disorders&rft.au=YANG+LIU&rft.au=HO%2C+Roger+Chun-Man&rft.au=MAK%2C+Anselm&rft.date=2012-08-01&rft.pub=Elsevier&rft.issn=0165-0327&rft.volume=139&rft.issue=3&rft.spage=230&rft.epage=239&rft_id=info:doi/10.1016%2Fj.jad.2011.08.003&rft.externalDBID=n%2Fa&rft.externalDocID=26042790 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01650327%2FS0165032712X00090%2Fcov150h.gif |